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Abstract 
Phenylalanine (Phe), an essential aromatic amino acid, serves as a 
precursor for protein synthesis and a variety of secondary metabolites in plants. 
Two pathways are known for Phe biosynthesis. In the first, prephenate 
dehydratases (PDTs) convert prephenate to phenylpyruvate, which is 
transaminated to Phe. In the second, prephenate is transaminated to arogenate, 
which is converted to Phe by arogenate dehydratases (ADTs). ADTs and PDTs 
are structurally very similar, as are their substrates. Six ADTs (ADT1-ADT6) have 
been identified in Arabidopsis thaliana. ADT1 and ADT2 can recognize both 
prephenate and arogenate as substrates whereas ADT3 – ADT6 are solely 
arogenate-accepting. Twenty ADT domain-swapping chimeras were generated 
through overlap extension PCR and were tested for PDT function in a pha2 
complementation assay. Through targeted mutagenesis it was identified that a 
Phe341Leu substitution in ADT5 was sufficient to introduce PDT function to this 
previously solely-arogenate accepting ADT. This research represents the first 
identification of any amino acid that discriminates an arogenate-only ADT from 
an ADT that is able to accept prephenate   
Keywords: Arabidopsis thaliana, phenylalanine biosynthesis, arogenate 
dehydratase, prephenate dehydratase, overlap extension PCR, pha2 
complementation assay, in silico analysis, ACT regulatory domain. 
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1 Introduction  
The research presented in this thesis is concerned with the final step of 
the phenylalanine (Phe) biosynthesis pathway in Arabidopsis thaliana. This 
step is catalyzed by arogenate dehydratases (ADTs). A family of six ADTs 
(ADT1-ADT6) have been identified in Arabidopsis.  
 
1.1 The importance of phenylalanine 
Phe is an aromatic amino acid that is synthesized through the 
shikimate pathway in plants, bacteria and fungi (Herrmann and Weaver 1999). 
Phe is required for protein synthesis in all organisms, and therefore is an 
important dietary component for organisms that cannot synthesize the amino 
acid themselves, such as humans. In the United States alone, approximately 
13,000 tons of Phe is artificially synthesized annually for use as a dietary 
supplement. This is valued at 198 million USD (Demain and Fang 2000). 
In plants, Phe is also a precursor to a diverse family of organic 
compounds. These compounds, such as flavonoids, alkaloids, lignin and 
suberin have a wide variety of important functions within the plant.  
Flavonoids are aromatic molecules that are created when Phe is 
converted to 4-coumaroyl-CoA (Falcone Ferreyra et al. 2012). These 
molecules represent the major red, blue and purple pigments in plants. These 
pigments recruit pollinators and seed dispersers (Winkel-Shirley 2001), which 
allow plants to improve their reproductive success. In addition, flavonoid 
pigments make flowering plants aesthetically pleasing and aesthetics such as 
these drive the success of the fast-growing flower industry. In 2012, flower 
and flower-related item sales were responsible for 27.8 billion dollars of 
revenue in the United States alone (U.S. Bureau of Economic Analysis, July 
31, 2013).  
Alkaloids are a class of nitrogen-containing organic compounds that 
are derived from Phe and tyrosine (Tyr; Facchini 2001). These molecules are 
key mediators of the plant’s resistance towards pests. For example, loline 
alkaloids, which are insecticidal compounds produced in grasses that are 
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infected with endophytic fungi, increase resistance of the infected grasses to 
aphid predation (Wilkinson et al. 2000).  
Lignin and suberin are Phe-derived biopolymers. Lignin is a broad term 
for a large group of complex cross-linking polymers of aromatic alcohols. This 
cross-linking framework is found in plant secondary cell walls and confers 
rigidity to the cell and stability to the plant as a whole (Vanholme et al. 2010). 
Lignin is also quite hydrophobic, which makes it very important for water 
conduction in vascular plants (Vogt 2010). Lignin crosslinking in the 
secondary plant cell wall acts as an obstacle for water absorption into the cell, 
and therefore lignin is a crucial component of cells involved in water transport, 
such as xylem tracheids (Peter and Neale 2004). In fact, lignin is one of the 
most abundant biopolymers on earth. Between 20 and 30% of the total carbon 
that is fixed through photosynthesis is channeled through the Phe 
biosynthesis pathway to the production of lignin, although this number differs 
greatly depending on whether the plant is woody or herbaceous (Bonawitz 
and Chapple 2010). Lignin has been a major focus of the biofuel industry due 
to its role in the inhibition of microbial fermentation of the plant cell wall. This 
inhibition decreases the efficiency of the energy conversion process in biofuel 
production, resulting in significant revenue losses (Frei 2013). 
Suberin is a cell wall biopolymer that is made up of both polyphenolic 
and polyaliphatic domains (Bernards 2002). Similar to lignin, suberin functions 
as a physical barrier to water movement within the plant. However, suberin 
also plays a significant role in the wound healing process of plants. Wounded 
plants focus their metabolic energy on the formation of this biopolymer, which 
can seal off the wound and therefore prevent infection (Yang and Bernards 
2007). For example, Soybean plants with increased suberin levels display 
partial resistance to Phytophthora sojae, a soil-born pathogen which causes 
root rot (Thomas et al. 2007). Root rot is responsible for millions of dollars of 
potential Soybean revenue losses every year (Kaufmann and Gerdemann 
1958).  
Phe is produced in plants and microorganisms but not humans. 
Therefore, enzymes in the Phe biosynthesis pathway can serve as drug 
targets against microbial pathogens (Husain et al. 2001), or herbicides against 
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invading plants (Tohge et al. 2013). In plants, the shikimate pathway has been 
a target for herbicidal inhibition in the past (Tohge et al. 2013).  
 
1.2 Phenylalanine biosynthesis  
Phe biosynthesis begins with the shikimate pathway in plants, fungi, 
and bacteria. The shikimate pathway is comprised of seven enzymatic 
reactions which lead to the production of chorismate (Herrmann 1995). 
Chorismate is the last common precursor of the three aromatic amino acids 
tryptophan (Trp), tyrosine (Tyr) and Phe. In Phe biosynthesis, chorismate is 
converted to prephenate by chorismate mutase (CM) (Herrmann and Weaver 
1999; Tzin and Galili 2010). Two steps are then necessary to convert 
prephenate to Phe: a decarboxylation/dehydration step and an 
aminotransferase step.  
The order of these two steps, as well as the enzymes that catalyze 
them, differ and therefore Phe biosynthesis can be divided into two pathways. 
These pathways are called the prephenate pathway and the arogenate 
pathway (Figure 1).  
In the prephenate pathway, prephenate is converted to phenylpyruvate 
via a decarboxylation/dehydration reaction. This reaction is catalyzed by a 
prephenate dehydratase (PDT; EC4.2.1.51). Phenylpyruvate is then 
converted to Phe by a phenylpyruvate aminotransferase (Cotton and Gibson 
1965; Fazel et al. 1980; Bentley 1990). In the arogenate pathway, prephenate 
is first transaminated to arogenate and arogenate is then converted to Phe in 
a decarboxylation/dehydration reaction that is catalyzed by an arogenate 
dehydratase (ADT; EC4.2.1.911). PDTs and ADTs both catalyze a 
decarboxylation/dehydration reaction, and recognize substrates (prephenate 
and arogenate, respectfully) that differ by only a single amino group (Figure 
1).  
 Microorganisms predominantly synthesize Phe via the prephenate 
pathway (Im and Pittard 1971). Plants, however, predominantly synthesize 
Phe 
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Figure 1. The last two steps of Phenylalanine biosynthesis. 
Chorismate, the end-product of the shikimate pathway, is converted to 
prephenate. In the prephenate pathway, prephenate is 
decarboxylated/dehydrated by a PDT to phenylpyruvate. Phenylpyruvate is 
then converted to phenylalanine by a PPAT. In the arogenate pathway, 
prephenate is first converted to arogenate by a PAT, and is then converted via 
a decarboxylation/dehydration reaction to phenylalanine by an ADT.  
PDT: prephenate dehydratase; PPAT: phenylpyruvate aminotransferase; 
PAT: prephenate aminotransferase; ADT: arogenate dehydratase. Modified 
from Bentley 1990. 
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via the arogenate pathway (Byng et al. 1981), with only one exception identified 
in the literature (Yoo et al. 2013) in which an aminotransferase was identified in 
Arabidopsis that could convert phenylpyruvate to phenylalanine. In addition, 
some microorganisms can use both the arogenate and the prephenate pathways 
to synthesize Phe (Zhao et al. 1992). These organisms employ enzymes called 
cyclohexadienyl dehydratases (CDTs), which can accept both arogenate and 
prephenate as substrates. However, CDTs are quite different from ADTs and 
PDTs at the sequence level.  
Some microorganisms employ a PDT-CM fusion protein, known as a P-
protein (Zhang et al. 1998). These proteins can both convert chorismate to 
prephenate and convert prephenate to phenylpyruvate.  
 
1.3 Sequence comparison of PDTs and ADTs 
While searching for putative PDT-domain encoding proteins in Arabidopsis 
thaliana, Cho et al. (2007) and Ehlting et al. (2005) identified a family of six PDT-
like enzymes. Through biochemical and yeast complementation analyses, these 
enzymes were shown to produce Phe predominantly via the arogenate pathway 
(Cho et al. 2007; Bross et al. 2011), and therefore were named ADT1-ADT6 
(ADT1, At1g11790; ADT2, At3g07630; ADT3, At2g27820; ADT4, At3g44720; 
ADT5, At5g22630; and ADT6, At1g08250). ADT1 and ADT2 contain introns, 
whereas ADT3-ADT6 do not.  
Phylogenetic analysis suggests that the bacterial and plant enzymes are 
evolutionarily distinct (Figure 2). The plant sequences used in this tree include 
the Arabidopsis ADTs listed above, as well as three Petunia hybrida ADTs 
(PhADT1: ACY79502.1; PhADT2: ACY79503.1; PhADT3: ACY79504.1) and five 
Oriza sativa ADTs (OsADT1: CBC52502.1; OsADT2: CBC52495.1; OsADT3: 
CBC52493.1; OsADT4: CBC87919.1; OsADT5: CAW84916.1). The bacterial 
sequences are listed in Table 1. When comparing the bacterial PDTs, the 
sequences branch into two groups: one containing Gram-positive bacteria and 
one containing Gram-negative bacteria, with the exception of Deinococcus 
radiodurans and Magnetococcus marinus, which are Gram-positive but cluster  
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Figure 2. Phylogenetic tree of plant ADTs and bacterial PDTs. 
Rooted phylogenetic tree generated with DNAMAN using a bootstrap of 1000. 
Branch point numbers represent the boot-strapping values and horizontal scale 
indicates sequence divergence. All sequences that are included in this tree 
contain both a catalytic domain and an ACT regulatory domain, the transit 
peptides of the plant sequences have been removed. Dashed lines separate the 
clustering of the plant sequences into subgroups and bacterial sequences into 
Gram-positive and Gram-negative groups (with the exception of Deinococcus 
radiodurans and Magnetococcus marinus, which are Gram-positive but cluster 
with the Gram-negative ADTs). The plant ADT sequences are highlighted in 
green and the enterobacterial PDT sequences are highlighted in yellow. A CDT 
sequence from Pseudomonas aeruginosa is included as a representative of 
these enzymes.
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Table 1. List of bacterial PDT sequences used in PDT sequence alignment. 
 
Bacteria Species 
 
Accession Number 
 
Amino Acids 
Removeda 
 
Gram Strain 
 
Agrobacterium tumefaciens 
 
EGL66829.1 
 
6 
 
Negative 
Bacillus anthracis WP_000621720.1 2 Positive 
Bacillus subtilis AEP91783.1 - Positive 
Bradyrhizobium japonicum WP_024340564.1 4 Negative 
Brucella suis AIB30268.1 7 Negative 
Chlorobium tepidum NP_662549.1 4 Negative 
Deinococcus radiodurans WP_010887790.1 - Positive 
Enterococcus faecalis WP_024797082.1 - Positive 
Erwinia herbicola CAH09395.1 - Negative 
Escherichia coli WP_001324213.1 - Negative 
Haemophilus influenzae AHL61944.1 - Negative 
Lactococcus lactis WP_011835672.1 1 Positive 
Listeria innocua 
 
WP_003767020.1 
 
1 
 
Positive 
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Table 1. (continued). List of bacterial PDT sequences used in PDT sequence alignment. 
Bacteria Species Accession Number 
 
Amino Acids 
Removeda 
Gram Stain 
    
Listeria monocytogenes AHN32779.1 1 Positive 
Magnetococcus marinus ABK44389.1 1 Positive 
Magnetospirillum magnetotacticum WP_018726497.1 9 Negative 
Mesorhizobium loti WP_019863035.1 6 Negative 
Pseudomonas aeruginosa WP_024914965.1 1 Negative 
Pseudomonas stutzeri AHL75120.1 1 Negative 
Rhizobium meliloti NP_384330 6 Negative 
Rhodopseudomonas palustris WP_013501421.1 1 Negative 
Salmonella typhimurius AGK68175.1 1 Negative 
Staphylococcus aureus AIA28436.1 1 Positive 
Streptococcus pneumoniae KDE93426.1 1 Positive 
Thermoanaerobacter tengcongensis NP_622663 7 Negative 
Vibrio cholerae 
 
NP_230354 
 
1 
 
Negative 
 
aNumber of amino acids removed from the N-terminus. 
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with the Gram-negative ADTs. In general, Gram-positive bacteria express a 
monofunctional enzyme while Gram-negative bacteria express a bifunctional P-
Protein.  
There is a high level of sequence diversity among the bacterial PDTs. For 
example, the bacterial sequences used in the phylogenetic alignment in Figure 2 
have an overall identity of only 45.8%. The PDTs from Chlorobidium tepidum and 
Staphylococcus aureus, which will be discussed further (section 1.6; Boavida et 
al. 2005) have a sequence identity of only 27.3% even though they are 
functionally very similar (Tan et al. 2008). Due to this diversity it is currently 
impossible to identify the exact amino acids that can distinguish between an ADT 
and a PDT based on the protein sequences alone.  
When aligned with ADT sequences from several other plant species, the 
six Arabidopsis ADTs branch into three subgroups (Figure 2). ADT1 and ADT2 
branch into Sub Groups I and II, respectively, and ADT3-ADT6 group together in 
Sub Group III. Of the Arabidopsis ADTs, ADT4 and ADT5 show the highest 
degree of sequence identity (82% identity).  
 
1.4 Substrate specificity  
1.4.1 Substrate specificity of ADTs in vitro 
In vitro biochemical analysis of the six Arabidopsis ADTs (Cho et al. 2007) 
indicates that all six enzymes preferentially accept arogenate as a substrate 
(Table 2). However, when tested for the ability to accept prephenate as a 
substrate, three of these enzymes (ADT1, ADT2 and ADT6) also displayed a low 
level of PDT function. The catalytic efficiency values (kcat/Km) of ADT1, ADT2 and 
ADT6 were 28, 32, and 98 times greater for arogenate recognition than 
prephenate, respectively. This dual substrate recognition can be found in ADT 
enzyme families in other plant species as well. For example, enzymes with the 
capacity to accept both arogenate and prephenate have also been identified in 
Petunia hybrida, in which two out of a family of three ADTs are also able to 
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Table 2. Ability of ADTs to use prephenate versus arogenate as a substrate. 
 
 
 
 
 
ADT 
 
Substratea 
 
 
 
 
Ability to 
Complement 
pha2b 
 
Arogenate 
 
Prephenate 
Vmax  
[pkat µg-1] 
 
kcat/Km  
[M-1 S-1] 
 
Vmax  
[pkat µg-1] 
 
kcat/Km  
[M-1 S-1] 
 
 
ADT1 
 
31.00 
 
1050 
 
0.28 
 
38 
 
Yes 
ADT2 60.60 7650 1.6 240 Yes 
ADT3 5.17 1140 - - No 
ADT4 52.32 490 - - No 
ADT5 11.26 620 - - No 
ADT6 
 
42.61 
 
1560 
 
0.4 
 
16 
 
No 
 
a: data from Cho et al., 2007. 
b: data from Bross et al., 2011. 
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accept prephenate as a substrate (Maeda et al. 2010). The catalytic efficiency 
values for arogenate recognition of these enzymes were approximately 100 and 
200 times greater than those for prephenate recognition. Before the results 
presented in this study, the specific amino acid sequence(s) that can distinguish 
an arogenate-only ADT from an arogenate- and prephenate-accepting ADT had 
not been identified. 
1.4.2 Substrate specificity of ADTs in vivo 
ADT1-ADT6 were subsequently tested for their ability to recognize 
prephenate as a substrate in a yeast complementation assay in vivo (Bross et al. 
2011). Saccharomyces cerevisiae, also called “bakers yeast”, utilizes only the 
prephenate pathway to produce Phe. The unicellular eukaryote contains one 
PDT gene, PHA2, which encodes for the only PDT protein in this organism. 
When PHA2 is knocked out, the yeast cannot survive without either an 
exogenous supply of Phe or a transformed gene that expresses a protein with 
PDT activity.  
The six ADT enzymes were expressed in a pha2 knockout S. cerevisiae 
strain. ADT1 and ADT2 were able to complement the PDT knockout phenotype, 
while ADT3-ADT6 were not. Although ADT6 displayed PDT function in the in vitro 
biochemical assays, it had the lowest prephenate catalytic efficiency (Table 2), 
and therefore it was understandable that it could not support growth in the in vivo 
assays. Thus, it was concluded that ADT1 and ADT2 are preferentially 
arogenate-accepting enzymes with low levels of prephenate recognition, and 
ADT3-ADT6 are solely arogenate-accepting enzymes (Bross et al. 2011).  
 
1.5 ADT and PDT domain organization 
Domain structures have been defined for both the plant ADTs and the 
bacterial PDTs (Cho et al. 2007)Figure 3). Both enzymes contain a catalytic 
domain and a C-terminal ACT domain, which is named after three of the proteins 
in its domain family (Aspartokinase, Chorismate mutase, TyrA).  
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In bacterial PDTs, the catalytic domain binds the prephenate substrate 
(Zhang et al. 2000; Hsu et al. 2004) and therefore it is hypothesized to be 
involved in substrate-binding in plant ADTs as well. Typically, ACT domain 
dimers bind specific amino acid ligands at their interface, resulting in the either 
the activation of inhibition of enzymatic function (Aravind and Koonin 1999; 
Liberles et al. 2005). ACT domain homologues are found in a wide range of 
enzymes that are regulated by amino acids, such as valine-inhibited acetolactate 
synthase, lysine-inhibited aspartokinase, and Phe-inhibited phenylalanine-4-
hydroxylase (Chipman and Shaanan 2001). In addition to the catalytic and ACT 
domain, plant ADTs contain an N-terminal transit peptide. The transit peptide 
was defined based on ~115 amino acids that don’t align with the bacterial PDTs 
and has been shown to target ADTs to the chloroplasts (Cho et al. 2007; Bross 
2011).  
When comparing PDTs across bacteria species, the ACT domain is more 
highly conserved than the PDT domain (Tan et al. 2008). When comparing the 
six Arabidopsis ADTs, the catalytic and ACT domains are the most highly 
conserved domains (62.0-97.8% and 61.5-91.7% similarity, respectively), 
whereas the transit peptide sequences are far more diverse (Crawley 2004) 
1.6 ADT and PDT 3D structure  
Three crystal structures exist in the literature for bacterial PDTs (Tan et al. 
2008; Vivan et al. 2008). These PDTs come from the bacterial species 
Mycobacterium tuberculosis, S. aureus, and C. tepidum. Although these 
enzymes have low protein sequence identity (32.22% overall) they have highly 
similar overall 3D structures. The structures support the domain organization just 
described (section 1.5). The catalytic domain is further divided into two 
subdomains: the PDTa and PDTb subdomains, which are each comprised of a 
central β-sheet in between three α-helices (Tan et al. 2008). The PDTb 
subdomain is inserted within the PDTa via two linker regions, and in between 
these two subdomains lies the catalytic cleft. This solvent accessible cleft is the 
site of prephenate binding in the bacterial PDT. The ACT domain is connected to 
the PDTa subdomain and interacts with this subdomain extensively.  
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Figure 3. Schematic of the domain structure of plant ADTs and bacterial 
PDTs.  
Both the plant and bacterial enzymes contain a catalytic domain (blue) and a C-
terminal ACT (Aspartokinase, Chorismate mutase, Tyr A) regulatory domain 
(green). In addition, the plant enzymes contain an N-terminal transit peptide 
(orange) for localization to the chloroplast.  
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Figure 4. Ct-PDT monomer and dimer 3D conformation. 
(A) Top: Ribbon drawing of the Chlorobium tepidum PDT monomer. The catalytic 
domain is divided into two subdomains: the PDTa and PDTb subdomains. The 
catalytic cleft is located in between the PDTa and PDTb subdomains and the 
ACT domain is attached to the PDTa subdomain Bottom: schematic of the PDT 
monomer in the closed (T) state (top view).  (B) Top: Ribbon drawing of the 
Chlorobium tepidum PDT homodimer, consisting of two monomers (blue and 
red). The dimer is shown in the closed (T) state and two phenylalanine molecules 
are shown bound to two pockets at the ACT dimer interface (beige). The catalytic 
clefts are indicated in the aligned PDTa subdomains. Bottom: schematic of the 
PDT dimer in the closed (T) state (top view). Original PDB file (2QMX) is from 
Tan et al., 2008 and images are obtained from UCSF Chimera  
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Two PDT monomers form a homodimer, the basic catalytic unit of the PDT 
enzyme (Tan et al. 2008; Vivan et al. 2008), with extensive interactions across 
both PDT and ACT domains (Figure 4B, top). The two catalytic clefts, one from 
each PDT monomer, align to form an extended active site across the interface of 
the PDT domain dimer (Tan et al. 2008). These clefts are in close proximity, 
indicating that there may be some communication between the two active sites 
during the decarboxylation/dehydration reaction. The ACT domains of the two 
monomers also align, creating two hydrophobic pockets at the ACT dimer 
interface. Two Phe molecules can simultaneously bind these hydrophobic 
pockets. When Phe is absent, the dimer exists in an open (“Relaxed”) state in 
which the prephenate substrate has access to the extended catalytic cleft formed 
between the two monomers. However, the binding of the two Phe molecules to 
the ACT dimer interface induces an overall conformational shift from this open 
(R) state to a closed (“Tense”) state, in which access to the cleft is greatly 
reduced (Tan et al. 2008; Figure 4, bottom; Figure 5). During this shift, the two 
ACT domains move closer to each other. This conformational change is 
propagated along the ACT-PDT interface, resulting in a shift in the PDT domains 
as well. The two PDTb subdomains push towards each other and the two PDTa 
subdomains move away from each other. This movement offsets the alignment 
of the extended catalytic cleft, reducing the access of prephenate to and the 
release of phenylpyruvate from the catalytic site and results in the allosteric 
inhibition of enzymatic function. Interestingly, PDTs are also able to form 
tetramers in solution, although the significance of these structures and their 
involvement in the allosteric conformational change is not currently known (Tan 
et al. 2008). 
Although there are no crystal structures available for the plant ADTs, the 
basic 3D structure of these enzymes can be estimated by homology modeling 
against the known PDT protein structures. For example, the ADT5 monomer can 
be modeled against the Ct-PDT monomer protein (Figure 6) using a 3D 
homology modeling program called UCSF Chimera. This program predicts that  
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Figure 5. Schematic of open (R) and closed (T) states of the PDT enzyme. 
A schematic of the allosteric regulation mechanism that is triggered when 
phenylalanine binds to the ACT domain interface of the bacterial PDT tetramer. 
Shown is the PDT homodimer, made up of two monomers (blue and red; bottom 
view). Binding of two phenylalanine molecules at the ACT interface between the 
two dimers results in an overall conformation shift that affects substrate binding 
in the catalytic sites of the complex. Adapted from Tan et al., 2008.  
	   21	  
	  
R-state T-state 
PDTb PDTa 
PDTb PDTa 
ACT ACT ACT ACT 
PDTa 
PDTb 
PDTb 
PDTa 
Catalytic site 
A" B"
	   22	  
	  
 
 
 
 
 
 
 
 
Figure 6. 3D homology modeling of ADT5 and Ct-PDT. 
(A) Ribbon diagram of the overlay of the PDT monomer from Chlorobium 
tepidum (blue) and homology modeled ADT5 from Arabidopsis thaliana (pink).  
(B) Ribbon diagram of homology modeled ADT5 (Model #1.2) from Arabidopsis 
thaliana. Original Ct-PDT PDB file is from Tan et al., 2008; PDB: 2QMX, images 
are obtained from UCSF Chimera and the homology modeled ribbon diagram 
was created using UCSF Chimera’s “Modeller” program.  
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although these two proteins share only 41.5% sequence identity, they have a 
very similar overall monomer structure.   
 
1.7 The importance of few amino acids 
The diversity in the bacterial PDT sequences makes it difficult to 
determine the amino acids that are important for prephenate substrate 
recognition. As a consequence of this, the exact amino acids responsible for 
prephenate recognition in plant ADTs are currently unknown. In Arabidopsis, two 
of the six members of the ADT family display both ADT and PDT function. 
Therefore, there must be some differences on the sequence level that can be 
used to identify this.  
Evidence in the literature suggests that enzymatic function can be 
converted between two similar proteins by introducing only a few amino acid 
substitutions to the protein sequence (Jäckel et al. 2008). This raises the 
question of where to look within the Arabidopsis ADTs for the amino acids that 
are responsible for PDT activity in ADT1 and ADT2. It seems intuitive that these 
amino acids would be located within the catalytic cleft, the part of the protein that 
is responsible for binding the substrate. However, it has been shown in other 
studies that mutations do not need to be within a proposed catalytic site to affect 
substrate specificity (Jeffery et al. 2000; Mendonça and Marana 2011). 
Therefore, in order to be exhaustive, the entire ADT protein sequence must be 
analyzed to find the amino acid(s) that can distinguish a prephenate-accepting 
ADT from a solely arogenate-accepting ADT.  
 
1.8 Thesis hypothesis and objectives 
ADTs and PDTs have many similarities. They have similar domain 
organization, they both catalyze a decarboxylation/dehydration reaction, and they 
recognize substrates that differ by only the presence of a single amino group. 
Due to these similarities, I hypothesize that PDT function can be introduced to an 
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arogenate-only Arabidopsis ADT (ADT3-ADT6) through the alteration of only a 
few amino acids. This research will identify the amino acid(s) that can distinguish 
between a prephenate-accepting ADT like ADT1 and ADT2 and a solely 
arogenate-accepting ADT like ADT3 – ADT6.  
My first objective is to narrow down the domain (transit peptide, catalytic, 
or ACT) that contains the sequences for prephenate recognition in the 
Arabidopsis ADTs. This will be accomplished by generating ADT chimeras 
containing domains from both a prephenate-accepting ADT (ADT1/ADT2) and an 
arogenate-specific ADT (ADT3-ADT6). Since it has been demonstrated that 
biochemical analysis may not reflect an in vivo system (Yao et al. 2007; Bross et 
al. 2011), I will test for PDT function of these ADT chimeras in a pha2 yeast 
complementation assay. Only chimeras with the domain that contains sequences 
that can confer PDT function will be able to sustain growth of this PDT knockout 
yeast strain.  
Once the domain(s) have been identified, my second objective is to revisit 
the sequence analysis and, through targeted amino acid substitutions and 
another yeast complementation assay, identify the exact amino acid(s) that can 
distinguish between a prephenate-accepting and a solely arogenate-accepting 
ADT. I have chosen ADT2 (both arogenate- and prephenate-accepting) and 
ADT4 and ADT5 (solely arogenate-accepting) for this research.  
 
2 Materials and Methods  
2.1 Media, buffers and gels  
2.1.1 Media 
For the creation of all solid media, 20 g of agar was added to 1 L of liquid 
media.  
Synthetic dextrose (SD) medium 
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Per 1 L: 20 g glucose, 6.7 g yeast nitrogen base without amino acids, 
1.5 g dropout powder (Amberg et al. 2005). Glucose was substituted with equal 
weights of galactose or raffinose as required.  
Yeast peptone dextrose (YPD) medium 
Per 1 L: 20 g glucose, 10 g yeast extract, 20 g bacto-peptone (Amberg et 
al. 2005).  
Amino acid dropout powder  
Per 25 L: 1 g adenine sulphate, 0.5 g L-arginine-HCL, 2.5 g L-aspartic 
acid, 2.5 g L-glutamic acid, 0.75 g L-isoleucine, 1.5 g L-leucine, 0.75 g L-lysine-
HCL, 0.5 g L-methionine, 1.25 g phenylalanine, 9.35 g L-serine, 5 g L-threonine, 
1 g L-tryptophan, 0.75 g L-tyrosine, 0.5 g uracil, 3.725 g L-valine (Sherman et al., 
1983), 2 mL histidine (His) liquid stock.  
Drop-out powder containing the appropriate amino acids for selection and 
functional testing were made from the above amino acids. 1.5 g of drop-out 
powder was used per 1 L of SD medium before autoclaving.  
Lysogeny broth (LB) 
Per 1 L: 10 g bacto-tryptone, 5 g yeast extract, 10 g NaCl, 200 µL 5 N 
NaOH (Sambrook and Russell 2001).  
Super Optimal Catabolite-Repression (SOC) medium 
 Per 1 L: 20 g bacto-tryptone, 5 g yeast extract, 2 mL 5 M NaCl, 2.5 mL 5 
M KCl, 10 mL 1 M MgCl2, 10 mL 1 M MgSO4, 20 mL 1 M glucose.  
Antibiotics  
Stock solutions of ampicillin (100 mg/mL), gentamycin (50 mg/mL) and 
kanamycin (60 mg/mL) were prepared by dissolving each in double distilled 
water. Dissolved antibiotics were filter sterilized (Sambrook and Russell 2001), 
aliquoted and stored at -20°C. Stocks were added to the media after autoclaving 
to a final concentration of 100 µg/mL, 15 µg/mL and 60 µg/mL for ampicillin, 
gentamycin and kanamycin, respectively.  
2.1.2 Buffers 
5x Sodium dodecyl sulfate protein sample buffer 
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Per 10 mL: 1.2 mL of 0.5 M Tris-HCl (pH 6.8), 2.5 mL 100% glycerol, 2 mL 
10% sodium dodecyl sulfate (SDS), 0.25 mL β-mercaptoethanol (BME), 0.5 mL 
2% (w/v) bromophenol blue, 3.55 mL double distilled water (Sambrook and 
Russell 2001).  
50x TAE buffer  
Per 1 L: 242 g Tris base, 57.1 mL glacial acetic acid, 100 mL 0.5 M 
ethylenediaminetetraacetic acid (EDTA) (pH 8.0), 1 L double distilled water. 50X 
TAE buffer was diluted to 1X with sterile double distilled water before use.  
Phosphate-buffered saline (PBS)/Tween-20 
Per 1 L: 8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4, 0.5 mL 
Tween-20 (Sambrook and Russell 2001). pH was adjusted to 7.4 with HCl.  
Yeast breaking buffer 
Per 1 L: 500 mL of 0.1 M sodium phosphate (pH 7.4), 2 mL of 0.5 EDTA 
(pH 8.0), 250 mL of 20% glycerol, 10 mL of 100 mM 
phenylmethanesulfonylfluoride (PMSF), 238 mL double distilled water 
(pYEST2/NT vector manual, Invitrogen Cat. No. V8252-20). 
2.1.3 Gels 
Agarose separating gel 
1% (w/v) agarose gels were used to separate and visualize PCR products 
and fragments from restriction enzyme digests.  
Per 30 mL: 30 mL 1x TAE buffer, 0.3 g of electrophoresis-grade agarose.  
Stacking gel 
10% (w/v) acrylamide separating gels were used to resolve proteins from 
S. cerevisiae (Sambrook and Russell 2001).  
Per 20 mL: 7.9 mL double distilled water, 6.7 mL 30% (w/v) acrylamide 
mix, 5 mL 1.5 M Tris (pH 8.8), 0.2 mL 10% SDS, 0.2 mL 10% ammonium 
persulfate (APS), 8 µL tetramethylethylenediamine (TEMED).  
 A 5% (w/v) stacking gel was also cast over the top of the 10% (w/v) 
separating gel. This allowed the loaded sample proteins to be concentrated into a 
tight band during the first few minutes of electrophoresis before entering the 
separating portion of the gel.  
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Per 10 mL: 6.8 mL water, 1.7 mL 30% acrylamide mix, 1.25 mL 1.0 M Tris 
(pH 6.8), 0.1 mL 10% SDS, 0.1 mL 10% APS, 10 µL TEMED (Sambrook and 
Russell 2001).  
 
2.2 Strains and plasmids  
2.2.1 Strains  
E. coli DH5α and DH10β strains (Invitrogen Cat. No. 11319019 and 
18290015, respectively) were used for maintenance and cloning of plasmid DNA. 
Liquid cultures were grown at 250 RPM at 37°C in LB. Cells harboring plasmids 
were grown in media supplemented with appropriate antibiotics for selection. 
The “pha2” haploid PDT knockout S. cerevisiae strain (pha2: Matα, 
his3Δ1, leu2Δ0, lys2Δ0, ura3Δ0, YNL316c::kanMX; Saccharomyces Genome 
Database; Invitrogen Cat. No. YSC1021-549308) was used for complementation 
assays. Yeast were grown at 30°C and liquid yeast cultures were grown at 220 
RPM.  
2.2.2 Plasmids 
The full-length ADT genes were cloned into a modified pEZT-NL vector 
(D. Ehrhardt, Carnegie Institution of Washington), where the 3’ GFP sequence 
was replaced with a CFP sequence by a previous student in the lab to allow the 
expression of a C-terminal CFP fusion protein (Bross et al. 2011). The inserts 
contain a start codon and lack a stop codon, to allow for the continuous 
expression of the CFP fusion protein.  
The pDONRTM221 (Figure 7A; Invitrogen Cat. No. 12536-017) vector was 
used as a donor vector. This vector contains an kanamycin marker for selection 
in E. coli.  
The pAG423GAL-ccdB-CFP yeast-compatible vector (Figure 7B; Alberti et 
al. 2007)  was used as a destination vector. This vector contains an ampicillin 
resistance marker for selection in E. coli and a His marker for selection in S. 
cerevisiae.  
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Figure 7. Gateway® compatible donor vector and destination vector. 
(A) Diagram of pDONRTM221 donor vector which contains attP sites for 
recombination with the attB sites that flank the PCR product, to generate the 
entry vector. Upon recombination, the ccdB gene is displaced by the gene insert. 
The KanR resistance gene is used for selection of the recombined entry vector in 
E. coli. (B) Diagram of the pAG423GAL-ccdB-ECFP destination vector. This 
vector contains attR sites for recombination with the attL sites in the entry vector 
to generate the expression vector. Upon recombination the ccdB gene is 
displaced by the gene insert. The AmpR resistance gene is used for selection of 
the recombined expression vector in E. coli and the HIS3 gene is used for 
selection of yeast the recombined expression vector.   
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 2.3 Cloning procedure  
Gateway® Cloning recombination technology was used to recombine the 
ADT inserts into a yeast compatible destination vector following the 
manufacturer’s manual (Invitrogen MAN0000282; Figure 8). Gateway® BP 
Clonase® II Enzyme mix (Invitrogen Cat. No. 11789020) was used for the 
recombination of the full-length ADTs and ADT chimeras into the pDONRTM221 
vector to generate the entry vector. Gateway® LR Clonase® II Enzyme mix 
(Invitrogen Cat. No. 11791100) was used for the recombination of the inserts into 
the pAG423GAL-ccdb-ECFP yeast-compatible destination vector.  
 
2.4 PCR amplification  
2.4.1 Primer Design:  
All primers were tested for self-complementarity, primer-pair 
complementarity, balanced GC content and similar melting temperatures within 
primer-pairs using DNAMAN (Lynnon BioSoft, Version 6; Table 3, Table 4).  
2.4.2 Overlap extension PCR 
Chimeras containing domains from both ADT2 and ADT4, or ADT2 and 
ADT5 were generated through overlap extension PCR (Figure 9). All PCR 
conditions were established using Tfi polymerase (Invitrogen Cat. No. 30342024) 
prior to amplification with Platinum Taq High Fidelity Polymerase (Invitrogen Cat. 
No. 11304011) (Table 5). PCR products were amplified using previously cloned 
ADT full-length gene sequences as a template (Bross 2011), as previously stated 
(section 2.2.2). Reactions were performed using a Touchgene Gradient 
Thermocycler (Techne TC-512; Cat. No. 353.55144.E1).  
Annealing temperatures varied based on the primers that were used in the 
reaction (Table 3; Table 4), and therefore are denoted as X in Table 6.  
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Figure 8. Schematic of Gateway® cloning strategy. 
(A) Each construct is recombined into the pDONRTM221 vector (blue). This is 
facilitated by the outer att recombination sites (orange) in a BP reaction, 
generates an entry vector. (B) The insert is then recombined from the entry 
vector into the pAG423GAL-ccdB-ECFP yeast compatible destination vector 
(green) using the att recombination sites (orange) in an LR reaction. This 
reaction generates an expression vector. Each expression vector is then 
transformed into pha2 yeast for the complementation assay.  
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Table 3. Primer sequences for domain swapping. 
Namea Sequence (5’ to 3’)b Directionc 
Annealing 
Temperature 
(°C)d 
 
attB1-ADT2FL* 
 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTTATGGCAATGC
ACACTGTT 
 
FWD 
 
65 
attB2-ADT2FL* GGGGACCACTTTGTACAAGAAAGCTGGGTAGAGCATTGTAG
TGTCCACTGG 
REV 65 
attB1-ADT4FL* GGGGACAAGTTTGTACAAAAAAGCAGGCTAGATGCAAGCCG
CAACGTCG 
FWD 65 
attB2-ADT4FL* GGGGACCACTTTGTACAAGAAAGCTGGGTATGCTTCTTCTGT
GGATGTCATGG 
REV 65 
attB1-ADT5FL* GGGGACAAGTTTGTACAAAAAAGCAGGCTATGCAAACCATTT
CGCCTGCG 
FWD 67 
attB2-ADT5FL* 
 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTACGTCTTCGCT
AGGTAACG 
 
REV 
 
67 
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Table 3. (continued). Primer sequences for domain swapping. 
Namea Sequence (5’ to 3’)b Directionc 
Annealing 
Temperature 
(°C)d 
 
ADT2/4CATACTF 
 
GCACCGTTGCATGGTTCTAGTCTACGTGTTGCGTATCAGGG
AGTACGAGGT 
 
FWD 
 
59 
ADT4/2TPR TCGTACTCCCTGATACGCAACACGTAGACTAGAACCATGCA
ACGGTGC 
REV 59 
ADT2/4TPCATR GGCAGCAAAGACGATGCTAGTCTTGAAGAGTCTGTTAGTTC
CAGGGATAATGGG 
REV 59 
ADT4/2ACTF CCCATTATCCCTGGAACTAACAGACTCTTCAAGACTAGCAT
CGTCTTTGCTGCC 
FWD 59 
ADT2/4ACTF CCTATAATCCCACGCACGGACCGGCCATTTAAGACAAGTAT
AGTTTTCTCGTTA 
 
FWD 59 
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Table 3. (continued) Primer sequences for domain swapping. 
Namea Sequence (5’ to 3’)b Directionc 
Annealing 
Temperature 
(°C)d 
 
ADT2/4TPR 
 
GGGAACGCCTTGGTAAGCTACACGAACGCGGGAGCCATT
AGAGACAGA 
 
REV 
 
59 
ADT4/2CATACTF TCTGTCTCTAATGGCTCCCGCGTTCGTGTAGCTTACCAAG
GCGTTCCC 
FWD 59 
ADT5/2MACTR CCTCCAGATGCTCGGAGAGGATGTTTCCTATGCGGCCGCG
ATTCGATTTTCGTC 
REV 67 
ADT2/5MACTF TTGACGAAAATCGAATCGCGGCCGCATAGGAAACATCCTC
TCCGAGCATCTGGAGG 
FWD 62 
ADT2/5MACTR CGCCTACGACTCTAAGGGGACAATTCTGTAAAGGGCGGC
TTTCAATCTTTGTGAG 
REV 62 
ADT5/2MACTF CTCACAAAGATTGAAAGCCGCCCTTTACAGAATTGTCCCG
TTAGAGTCGTAGGCG 
 
FWD 65 
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Table 3. (continued). Primer sequences for domain swapping. 
Namea Sequence (5’ to 3’)b Directionc 
Annealing 
Temperature 
(°C)d 
 
ADT5/2MCATR 
 
GGCTAAGCACCCTTCTCAAATCTTCAATACGAACTCCGGGA
AGAGCTAAGAGACAG 
 
REV 
 
65 
ADT2/5MCATF CTGTCTCTTAGCTCTTCCCGGAGTTCGTATTGAAGATTTGAG
AAGGGTGCTTAGCC 
FWD 62 
ADT2/5TPR AACTCCTTGATACGCGACACGAACGCGGGAGCCATTAGAGA
C 
REV 65 
ADT5/2CATACT
F 
TGTCTCTAATGGCTCCCGCGTTCGTGTCGCGTATCAAGGAG
TTC 
FWD 67 
ADT2/5TPCATR GAAAACTATACTTGTCTTAAAGAGTCTGTTAGTTCCAGGGAT REV 62 
ADT5/2ACTF ATTATCCCTGGAACTAACAGACTCTTTAAGACAAGTATAGTT
TTCTCG 
 
FWD 65 
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Table 3. (continued). Primer sequences for domain swapping. 
Namea Sequence (5’ to 3’)b Directionc 
 
Annealing 
Temperature (°C)d 
 
 
ADT2/5CATACTF 
 
CGCCGTCTCATGGATCTACTCTTCGTGT
TGCGTATCAGGGAGTACG 
 
FWD 
 
65 
ADT5/2TPR TACTCCCTGATACGCAACACGAAGAGTA
GATCCATGAGACGG 
REV 65 
ADT2/5ACTF ATCATTCCCCGTACCGATCGTCCGTTTA
AGACAAGTATAGTTTTCTCG 
FWD 62 
ADT5/2TPCATR AGAAAACTATACTTGTCTTAAACGGACGA
TCGGTACGGGGAATG 
 
REV 62 
a*: outer primer; bdouble underline: 5’ GGGG for docking of Gateway® enzymes; bold: attB1/attB2 sequences; bold and 
underlined: added to maintain frame; italics: complementary to ADT2; underlined: complementary to ADT5; non-
annotated: complementary to ADT4; cFWD: forward amplification; REV: reverse amplification. dAnnealing temperatures 
listed for outer primers were used for full-length ADT and chimera amplification, and those listed for the inner primers 
were used for overlap extension PCR.  
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 Table 4. Primer sequences for targeted mutagenesis. 
Name Sequence (5’ to 3’)a Directionb 
 
Annealing 
Temperature 
(°C)c 
 
 
5-V397LF 
 
CGCGTTAGCGGAGTTGCAAGAGTACACGTCATTCC 
 
FWD 
 
60 
5-V397LR GGAATGACGTGTACTCTTGCAACTCCGCTAACGCG REV 63 
4-V396LF CGCGCTTGCGGAGCTTCAAGAGTACACGTCGTTCC FWD 60 
4-V396LR GGAACGACGTGTACTCTTGGAACTCCGCAAGCGCG REV 60 
5-F341LF GTGCTTTCCGCGTTTGCGCTTCGAAACATTAGTTTGACG FWD 62 
5-F341LR CGTCAAACTAATGTTTCGAAGCGCAAACGCGGAAAGCAC REV 62 
5-S345NF 
 
 
GCGTTTGCGTTTCGAAACATTAATTTGACGAAAATCGAATCG
CGGCCG 
 
FWD 
 
 
64 
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Table 4. (continued). Primer sequences for targeted mutagenesis.  
Name Sequence (5’ to 3’)a Directionb 
 
Annealing 
Temperature 
(°C)c 
 
5-S345NR 
 
CGGCCGCGATTCGATTTTCGTCAAATTAATGTTTCGAAACGCA
AACGC 
REV 64 
5-DM-F 
 
GTGCTTTCCGCGTTTGCGCTTCGAAACATTAATTTGACGAAAA
TCGAATCGCGG 
FWD 
 
64 
 
5-DM-R 
 
 
CCGCGATTCGATTTTCGTCAAATTAATGTTTCGAAGCGCAAAC
GCGGAAAGCAC 
 
REV 
 
 
64 
 
 
aBold and double-underlined: nucleotide substitutions; Underlined: complementary to ADT5; non-underlined: 
complementary to ADT4; bFWD: forward amplification; REV: amplification. These primers were used in combination with 
the outer primers listed in Table 2. cAnnealing temperature for overlap extension PCR. 
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Figure 9. Schematic of overlap extension PCR. 
(A) Fragments containing 15-24 bp of overlapping sequences are generated in a 
first set of PCRs using outer primers that are specific to the template (straight 
arrows) and inner primers that contain a combination of sequences from both of 
the ADT templates (curved arrows). (B) In a third PCR reaction, both fragments 
that were generated in (A) are used as templates. The overlapping sequences 
facilitate the annealing of the fragments, and the DNA polymerase extends from 
the fragments’ 3’ ends, generating the full-length sequence. Only the outer 
primers are used in this reaction, ensuring that the full-length chimera is 
amplified.  
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Table 5. Components for fragment amplification and overlap extension 
PCR. 
 
Component 
 
Final Concentration 
 
10 High Fidelity PCR Buffer 
 
1X 
10 mM MgSO4 2.0 mM 
10 mM dNTP Mix 0.2 mM each 
10 µM Forward Primer 0.2 µM 
10 µM Reverse Primer 0.2 µM 
Template DNA* <500 ng 
Platinum® Taq DNA Polymerase 
High Fidelity (5 U/µL) 
1 U/rxn 
Autoclaved, distilled water 
 
- 
 
*For overlap extension PCR reactions: the two templates to be recombined were 
both added to this final concentration.  
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Table 6. Thermocycler conditions for fragment amplification and overlap 
extension PCR. 
 
Cycle 
 
Temperature (°C) 
 
Time 
 
Number of 
Cycles 
 
 
Initial denaturation 
 
94 
 
 
10 min 
 
 
1 
 
Denature 94 15 secs 
 
 
5* Annealing 55 30 secs 
Extension 
 
72 
 
1 min 
 
 
Denature 
 
94 
 
15 secs 
 
 
30 Annealing X 30 secs 
Extension 
 
72 1 min 
 
 
Final extension 
 
 
72 
 
7 min 
 
1 
*For 5-SLEEG and 5-F341L overlap extension PCR: the number of cycles for 
these PCR reactions was increased to 10 and primers were not added until after 
these 10 cycles were complete.
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The 5-SLEEG and 5-F341L full-length constructs (see section 2.5 for more 
information on these chimeras) could not be successfully amplified through over-
lap extension PCR with the standard cycle conditions, and so a modified protocol 
was used. In this modified protocol, the number of cycles at a 55°C annealing 
temperature was increased from five to ten, and primers were only added to the 
reaction after these cycles were complete (Table 6). This was done to ensure 
that the overlapping sequences would anneal first and the DNA polymerase 
would extend from the 3’ ends of the fragments, generating the full-length 
product. Then, once the primers were added, this full-length product was used as 
the template.  
M13 primers were used for sequencing all of the ADT inserts in the entry 
vectors.  
 
2.5 Chimera name annotation  
The chimeras are named based on the protein sequences. All descriptions 
and positions correspond to the amino acid level.  
The six chimeras that contained domain sequences from ADT2 and ADT4 
were the first six chimeras to be generated, and therefore these constructs are 
named Chimera 1 – Chimera 6 (Figure 10). The next seven chimeras that were 
generated contained domain sequences from ADT2 and ADT5 and were named 
Chimera 7 – Chimera 13 (Figure 11).  
The chimeras that swap the nucleotides that correspond to the SLEEG 
motif in the ACT domain of ADT2 and ADT5 were named 2-SLEEG and 5-
SLEEG, respectively. 2-SLEEG has the nucleotide sequences that correspond to 
the entire ADT2 transit peptide and catalytic domain, and the N-terminal ACT 
domain sequence until G299, ADT5 sequences from the corresponding ADT5 
amino acid (S331) make up the C-terminal end of the ACT domain in this 
chimera. 5-SLEEG has the nucleotide sequences that correspond to the entire 
ADT5 transit peptide and catalytic domain, and the N-terminal ACT domain  
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Figure 10. Schematics for ADT2/ADT4 chimeras. 
Full-length ADT2 (white) and ADT4 (purple) were assembled through overlap 
extension PCR to generate Chimera 1 – Chimera 6, which have every possible 
combination of the three ADT domains.  
TP: transit peptide; CAT: catalytic domain; ACT: ACT regulatory domain.  
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Figure 11. Schematics for ADT2/ADT5 chimeras. 
Full-length ADT2 (white) and ADT5 (green) were assembled through overlap 
extension PCR to generate Chimera 7 – Chimera 13 which have every possible 
combination of the three ADT domains.  
TP: transit peptide; CAT: catalytic domain; ACT: ACT regulatory domain.  
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sequences until S331 and ADT2 sequences make up G299 to the C-terminal 
ACT domain (Figure 12).  
The chimeras that contain the nucleotide mutations that result in a single 
amino acid substitution are named as follows: (the ADT template) – (native 
amino acid) (position) (substituted amino acid). For example, the chimera named 
5-F341L contains the nucleotide sequences that express the transit peptide, 
catalytic and ACT domains from ADT5 with the exception that a Phe has been 
substituted for a Leu at amino acid position 341 (Figure 12).  
For the overlap extension PCR, the fragments that contain overlapping 
sequences for the amplification of the ADT construct are named “Fragment Xa” 
or “Fragment Xb”, where X represents the chimera number or name. For 
example, the overlapping fragments that were used as templates to generate 
Chimera 1 through overlap extension PCR are named Fragment 1a and 
Fragment 1b.  
 
2.6 Gel purification and quantification of DNA  
DNA fragments were size separated by gel electrophoresis on a 1% (w/v) 
agarose gel in TBA buffer. The DNA was stained with RedSafeTM Nucleic Acid 
Staining Solution (FroggaBio Cat. No. 21141) and visualized under UV light. 
Fragments of the correct size (Table 7; Table 8; Table 9) were excised from the 
gel and were purified using the PureLink Quick Gel Extraction Kit (Invitrogen Cat. 
No. K210012). Samples were resuspended in 50 µL of Elution Buffer (“E5” 
provided in the kit; 10mM Tris-HCL, pH 8.5) and the DNA concentration and the 
260/280 values were measured using a NanodropTM 1000 Spectrophotometer 
(Thermo Scientific Cat. No. ND-1000). DNA fragments were considered 
acceptable for use in PCR or cloning if the concentration was between 25 and 
75 ng/µL and the 260/280 values were between 1.7 and 1.9.  
If sample concentration was between 10 ng/µL and 25 ng/µL, samples 
were evaporated using a ScientificTM SavantTM DNA SpeedVacTM Concentrator  
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Figure 12. Schematics for N-terminal ACT domain constructs. 
Overlap extension PCR was used to generate 2-SLEEG, 5-SLEEG, 5-F341L, 5-
S345N, 5-DM, 5-V397L, and 4-V396L constructs using ADT2, ADT4, and ADT5 
templates.  
TP: transit peptide; CAT: catalytic domain; ACT: ACT regulatory domain.  
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Table 7. Composition and expected lengths of ADT2/ADT4 chimeras. 
Fragments and 
Chimeras 
ADT2 Domains ADT4 Domains 
 
Length  
nt aa MWa 
 
Fragment 1a 
 
TP 
 
 
 
315 
  
Fragment 1b  CAT, ACT 918   
Fragment 2a CAT, ACT  867   
Fragment 2b  TP 393   
Fragment 3a TP, CAT  813   
Fragment 3b  ACT 354   
Fragment 4a  TP, CAT 329   
Fragment 4b ACT  957   
Fragment 5a CAT TP 1020   
Fragment 5b  ACT 296   
Fragment 6a TP CAT 341   
Fragment 6b 
 
ACT 
 
 
1011 
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Table 7. (continued). Composition and expected lengths of ADT2/ADT4 
chimeras.  
 
Fragments and 
Chimeras  
ADT2 Domains ADT4 Domains 
 
Length  
nt aa MWa 
 
FL ADT2 
 
TP, CAT, ACT 
 
 
1146 
 
381 
 
42.1 
FL ADT4  TP, CAT, ACT 1275 424 45.9 
Chimera 1 TP CAT, ACT 1197 398 43.8 
Chimera 2 CAT, ACT TP 1224 407 44.3 
Chimera 3 TP, CAT ACT 1291 396 43.8 
Chimera 4 ACT TP, CAT 1210 409 44.3 
Chimera 5 CAT TP, ACT 1300 422 46 
Chimera 6 
 
TP, ACT 
 
CAT 
 
1292 
 
384 
 
44.1 
 
Amino acid length and molecular weight are only listed for chimeras used in the 
Western Blot. nt: nucleotide length; aa: amino acid length; MWa : molecular mass 
in kDa of the native protein. Add 27.7 kDa to this value for the molecular weight 
of the ADT-ECFP fusion protein. 
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Table 8. Composition and expected lengths of ADT2/ADT5 chimeras. 
Fragments and 
Chimeras  
ADT2 Domains ADT5 Domains 
 
Length 
nt aa MWa 
 
Fragment 7a 
 
TP 
 
 
 
297 
  
Fragment 7b  CAT, ACT 900   
Fragment 8a TP, CAT  795   
Fragment 8b  ACT 336   
Fragment 9a CAT, ACT  995   
Fragment 9b  TP 278   
Fragment 10a ACT  341   
Fragment 10b  TP, CAT 962   
Fragment 11a  TP, CAT, N-ACT 1071   
Fragment 11b ACT-C  237   
Fragment 12a TP, CAT, N-ACT  1039   
Fragment 12b  ACT-C 264   
Fragment 13a  TP, N-CAT 660   
Fragment 13b 
 
CAT-C, ACT 
 
 
 
600 
 
  
 
	   56	  
	  
 
 
 
 
 
Table 8.  (continued). Composition and expected lengths of ADT2/ADT5      
               chimeras. 
Fragments and 
Chimeras 
ADT2 Domains ADT5 Domains 
 
Length  
nt aa MWa 
 
FL ADT2 
 
TP, CAT, ACT 
 
 
 
1146 
 
381 
 
42.1 
FL ADT5  TP, CAT, ACT 1278 425 45.9 
Chimera 7 TP CAT, ACT 1217 398 43.5 
Chimera 8 TP. CAT ACT 1361 396 43.7 
Chimera 9 CAT. ACT TP 1267 408 44.5 
Chimera 10 ACT TP, CAT 1203 410 44.3 
Chimera 11 ACT-C TP, CAT, N-ACT 1328 411 44.5 
Chimera 12 TP, CAT, N-ACT ACT-C 1223 367 40.31 
Chimera 13 
 
CAT-C, N-ACT 
 
TP, N-CAT 
 
1210 
 
355 
 
38.4 
 
Amino acid length and molecular weight are only listed for chimeras used in the 
Western Blot. nt: nucleotide length; aa: amino acid length; MWa : molecular 
weight in kDa of the native protein. Add 27.7 kDa to this value for the molecular 
weight of the ADT-ECFP fusion protein; N-: N-terminal sequences; -C: C-terminal 
sequences.  
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Table 9. Composition and expected lengths of ACT domain chimeras. 
Fragments and 
Chimeras  
ADT2 Domains 
 
ADT4 Domains 
 
ADT5 Domains 
 
Length 
nt aa MWa 
 
5-F341La 
 
 
 
 
 
ACT-Cb 
 
306 
 
 
 
 
5-F341Lb   TP, CAT, N-ACTb 994   
5-S345Na   TP, CAT, N-ACTc 1084   
5-S345Nb   ACT-Cc 226   
5-DMa   TP, CAT, N-ACTd 1092   
5-DMb   ACT-Cd 232   
5-SLEEGa ACT-Ce   1052   
5-SLEEGb   TP, CAT, N-ACTf 267   
2-SLEEGa TP, CAT, N-ACTg   270   
2-SLEEGb   ACT-Ch 1117   
4-V396La  TP, CAT, N-ACTi  1207   
4-V396Lb  ACT-Ci  146   
5-V397La 
 
 
 
 
 
TP, CAT, ACTj 
 
1216 
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Table 9. (continued). Composition and expected lengths of ACT domain chimeras. 
Fragments and 
Chimeras  
ADT2 Domains ADT4 Domains ADT5 Domains 
 
Length 
nt aa MWa 
 
5-V397Lb 
 
 
 
 
 
ACT-Cj 
 
168 
 
 
 
 
5-F341L   TP, CAT, ACTb 1278 425 46.0 
5-3S45N   TP, CAT, ACTc 1278 425 46.0 
5-DM   TP, CAT, ACTd 1278 425 45.9 
5-SLEEG ACT-C e  TP. CAT. N-ACTf 1269 412 44.6 
2-SLEEG TP, CAT, N-ACTg  ACT-Ch 1236 394 43.5 
4-V396L  TP, CAT, ACTi  1275 424 46.0 
5-V397L 
 
 
 
 
 
TP, CAT, ACTj 
 
1278 
 
425 
 
46.0 
 
Amino acid length and molecular weight are only listed for chimeras used in the Western Blot. nt: nucleotide length; aa: 
amino acid length; MWa molecular weight in kDa of the native protein. Add 27.7 kDa to this value for the molecular weight 
of the ADT-ECFP fusion protein; N-: N-terminal sequences; -C: C-terminal sequences; b: sequences with 1021T>C 
substitution; c: sequences with 1034G>A substitution; d: sequences with both 1021T>C and 1034G>A substitutions; e: 
sequences from 898G to C-terminus; f: sequences from N-terminus to 1012G; g: sequences from N-terminus to 898G; h: 
sequences from 1012G to C-terminus; i: sequences with 1186G>T substitution; j: sequences with 1189G>C substitution. 
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(Thermo Scientific Cat. No. 20-548-132) and resuspended in sterile double 
distilled water to increase the concentration to within the acceptable range. 
  
2.7 Plasmid DNA isolation, DNA sequencing and analysis  
Plasmid DNA was isolated from DH5α E. coli using an alkaline lysis with 
SDS miniprep protocol (Sambrook and Russell 2001). Plasmid DNA for 
sequencing was isolated using the QIAprep Spin Miniprep Kit (QIAGEN Cat. No. 
12123). Isolated DNA concentration and quality was analyzed using NanodropTM 
1000 Spectrophotometer (Thermo Scientific Cat. No. ND-1000).  
Entry vectors were sent to the London Regional Genomics Centre in the 
Robarts Research Institute for sequencing and only inserts lacking mutations 
were used for functional analysis (The University of Western Ontario).  
 
2.8 Transformations 
2.8.1 E. coli transformations 
DH5α E. coli cells were made chemically competent through a Rubidium 
Chloride Competent Cell procedure (Renzette 2011) and plasmid DNA was 
transformed into the competent E. coli cells using the One Shot® TOP10 
Chemically Competent E. coli transformation procedure (Invitrogen Cat. No. 
C4040-03 Manual). All liquid cultures of E. coli were grown at 37°C and 225 RPM 
unless otherwise stated. Alterations to the transformation procedure were as 
follows: incubation time in a 37°C shaker was increased to 1.5 hours immediately 
following the heat shock, and the amount of cells plated on solid selective LB 
was increased to 250 µL.  
Transformed E. coli cells were plated on solid selective LB plates and 
incubated at 37°C overnight. Colonies were picked the next day and grown 
overnight in liquid selective LB. Bacterial stocks were stored in 25% sterile 
glycerol at -80°C.  
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2.8.2 pha2 yeast transformations 
S. cerevisiae pha2 cells were made competent and transformed using the 
lithium acetate/single stranded carrier DNA/polyethylene glycol method (Gietz 
and Woods 2002). Yeast was transformed with one of the following: an ADT 
chimera, full-length ADT2, ADT4 or ADT5, or the empty pAG423GAL-ccdB-
ECFP destination vector. Cells were plated on appropriately supplemented solid 
selective SD media and incubated at 30°C for 3 to 7 days. Yeast colonies were 
then re-streaked on the same type of media, incubated at 30°C for 3 more days, 
and were stored in 15% (w/v) sterile glycerol at -80°C. For all yeast experiments, 
cell density was determined by counting yeast cells using a Bright-LineTM 
Haemacytometer (Sigma-Aldrich Cat. No. Z359629).  
 
2.9 Protein induction, isolation and detection in S. cerevisiae 
A Western blot assay was used to determine if the pha2 yeast was able to 
express the ADT proteins. Samples for this assay included yeast that contained 
the ADT chimeras, ADT2, ADT4 or ADT5 full-length proteins, or the empty 
destination vector, untransformed yeast, and non-induced yeast which contained 
Chimera 8 but what grown in non-inducing medium. All yeast cultures were 
grown in liquid media at 30°C and 225 RPM unless otherwise stated.  
 First, pre-cultures of the yeast samples were grown in appropriately 
supplemented non-inducing liquid media (raffinose; West Jr et al. 1984) for 24 
hours. The cells were harvested in mid-late logarithmic growth phase (~7 x 106 -7 
x 107) by centrifuging at 1500 x g for 5 minutes. They were then transferred to 
appropriately supplemented inducing liquid media (galactose; West Jr et al. 
1984), with the exception of the non-induced sample which was transferred to 
appropriately supplemented non-inducing liquid media (glucose; West Jr et al. 
1984). They were grown for approximately 24 hours and cells were collected at a 
cell density of 5 x 106 cells/mL. Cell lysates were prepared according to the 
manufacturer’s instruction manual for the pYES2/NT vector (Invitrogen Cat. No. 
V8252-20). The total soluble protein (TSP) was quantified using a PierceTM BCA 
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Protein Assay Kit (Pierce Cat. No. 23227; Smith et al. 1985) and samples were 
diluted to 750 µg/mL of protein and stored at -80°C in 5X denaturing SDS buffer 
with BME until the Western blot assay.  
 Fifteen µg of TSP from each sample was size separated on a 10% 
(w/v) SDS-PAGE. A Precision Plus ProteinTM Dual Color Standards ladder 
(BioRad Ca. No. 161-0374) and a GFP-hydrophobin standard (1:1000 dilution; 
Gutiérrez et al. 2013) were also loaded. The proteins were transferred to a 
nitrocellulose membrane (Invitrogen Cat. No. LC2000) using a semi dry transfer 
method (Towbin et al. 1979) and probed with primary anti-GFP antibody (1:5000 
antibody dilution of A.v. monoclonal antibody (JL-8), Clontech Cat. No. 632380). 
The anti-GFP antibody was used because CFP and GFP are similar enough that 
both can be detected with this antibody (Bross et al. 2011). Subsequently, the 
blot was probed with a goat anti-mouse IgG (H+L)-horseradish peroxidase 
conjugated antibody (1:3000 dilution, Bio-Rad Cat. No. 170-6516). An enhanced 
chemiluminescence (ECL) detection system (GE Healthcare Cat. No. RPN2109) 
was used for visualization. Western blots were exposed for 1 minute and imaged 
using X-ray film.  
 
2.10 Yeast complementation assays  
PDT activity was tested for in a pha2 yeast complementation assay 
(Figure 13). The yeast samples described in the previous section (section 2.7) 
were grown in appropriately supplemented liquid raffinose media for 24 hours 
and were harvested at a cell density of at least 5 x 106 cells/mL. All liquid yeast 
cultures were grown at 30°C and 225 RPM unless otherwise stated. Aliquots of 
each were then centrifuged at 13000 x g for 30 seconds and resuspended in 
sterile double distilled water to a final concentration of 1 x 105 cells/mL.  
All samples and controls were tested on plates of solid SD media. These 
plates contained either glucose (which represses the GAL1 promoter in the 
destination vector), raffinose (which neither represses or induces GAL1) or 
galactose (which induces GAL1) as a carbon source. Plates within each carbon
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Figure 13. Schematic of complementation assay to test for PDT function. 
(A) ADT chimeras are recombined into the yeast compatible destination vector. 
pha2 yeast are transformed with the destination vector carrying an ADT insert. 
(B) Yeast transformants are spotted on selective solid SD media containing 
galactose as a carbon source to induce transcription (right-facing arrow) from the 
GAL1 promoter (light green). The yeast transformants were spotted on solid SD 
media containing Phe as a positive control (green checkmark). Transformants 
were spotted on solid selective SD media lacking Phe to test for PDT function 
(purple question mark). Note: yeast transformants were also spotted on solid SD 
media containing glucose or raffinose as a carbon source.  
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 source were divided into three treatments: one that was fully-supplemented, one 
which selected for transformed yeast (lacking His), and one which tested for PDT 
function (lacking His and Phe). pha2 transformant liquid cultures of 10 µL were 
spotted on each plate and growth was documented for 30 days.  
 
2.11 3D Homology Modeling  
UCSF Chimera was used for all molecular graphics and analyses presented 
in this study. The UCSF Chimera program was developed by the Resource for 
Biocomputing, Visualization and Informatics and the University of California, San 
Francsisco and is supported by NIGMS (P41-GM103311).  
To predict the structure and the position of the amino acids for distinguishing 
between a prephenate –accepting ADT and a solely arogenate-accepting ADT,  
in ADT2 and ADT5, the ADT2 and ADT5 protein sequences were homology 
modeled against a protein template with a known structure. Chimera’s “BLAST 
Protein” tool was used to identify the protein structure that has the highest 
similarity to ADT2 and ADT5. The ADTs were modeled to Chain A of the PDT 
protein from C. tepidum (PDB file 2QMX_A; Tan et al. 2008) using the “Modeller” 
tool. The program used two scores, a GA341 and a zDOPE score, to measure 
the quality of the models that were generated with this tool. The GA341 model 
score is derived from statistical potentials and a value greater than 0.7 generally 
indicates a reliable model (>95% probability of having the correct fold (Pettersen 
2004). The zDOPE score, also known as the Discrete Optimized Protein Energy 
(DOPE) score, is a sample of native structures that do not depend on adjustable 
parameters and is based on an improved reference state that accounts for the 
spherical shape of the native structures. This score is used to derive an atomic 
distance-dependent statistical potential from a sample of native structures and a 
more negative zDOPE score indicates a better model (Pettersen 2004).  
Amino acid substitutions were made using the Chimera’s “Rotamers” tool and 
the Dunbrack Rotamer library (Dunbrack Jr 2002). Interatomic “clashes” 
(unfavourable interactions in which atoms are too close together) and “contacts” 
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(both polar and nonpolar interactions) were found in atoms with a Van der Waal 
radius overlap of greater than or equal to 0.6 Ångstroms using the  “Clashes & 
Contacts” tool. The “FindHBond” tool was used to identify potential hydrogen 
bonds between the amino acids of interest and their surrounding amino acids.  
 
3 Results  
3.1 in silico analysis of ADTs and PDTs 
An in silico approach was used to identify amino acids that can potentially 
differentiate between the prephenate-accepting and the solely arogenate-
accepting ADTs. To do this, both ADT and PDT protein sequences were 
analyzed and compared.  
  First, PDT protein sequences were selected from 26 different bacterial 
species (Table 1). These 26 bacteria were chosen so that they represent a 
diverse set of species. For example, sequences from both Gram-negative and 
Gram-positive bacteria were included. In contrast to Arabidopsis and other plant 
species that have ADT families, bacteria contain only one PDT. The goal of this 
alignment was to identify amino acids that were common to the PDTs. It was 
assumed that if an amino acid was important for PDT function it would be 
conserved among the bacterial PDTs in this alignment. However, there is a high 
level of sequence diversity between the bacterial sequences. For example, some 
sequences chosen for the alignment were only 24.6% identical, and there was an 
average of 45.8% identity within the entire group. Amino acids that were identical 
in 100% of the sequences were in highly conserved motifs that are known to be 
important for overall enzyme function (data not shown), and therefore unlikely to 
distinguish between an ADT and a PDT. Therefore, 100% identity was 
considered to be too stringent. Instead, amino acids that were similar in more 
than 75% of the sequences were identified. Forty amino acids were identified and 
are highlighted in blue in Figure 14.  
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Figure 14. Protein sequence alignment of bacterial PDTs. 
Alignment of 27 PDT protein sequences from bacteria generated with DNAMAN. 
Dots: spacing introduced by the DNAMAN alignment program; blue highlight: 40 
amino acid locations that were identified as similar in more than 75% of the 
bacterial sequences; yellow highlight: the 16 of 18 amino acid sites identified in 
the Arabidopsis ADT alignment that could be located; star: the 10 amino acid 
sites identified in the Arabidopsis ADT alignment that contained both the amino 
acid from ADT1/ADT2 and the amino acid from ADT3 – ADT6; arrow: the 6 
amino acid sites identified in the Arabidopsis ADT alignment that did not contain 
the amino acid found in ADT3 – ADT6; green arrow: the amino acid position that 
corresponds to the Phe341Leu substitution in ADT5 (discussed in section 3.5).  
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RVGYLGPEATFTNMAVSRFFP....EAEHVPYRTIPDCMDAAANGNVDYAVVPLENAIEGSVNITVDYLVH.EQP
KVGYLGPAATFTHLAVSSCFQN...GAEHVAYRTIPECIDAAVAGEVDFAFVPLENALEGSVNLTIDYLIH.EQP
KIGYLGPRGTFTEMAVQTLFDD...KNVLKPYRTIPDCMDSVANGDMDAAVVPVENAIEGSVNVTLDYLIH.KQR
KIAYLGPAASFTHAAAAKAFP....KEEMVAKSTIPDCIMAIEKEDVDVAVVPIENTIEGSVNITLDYLFH.FSS
KIAYLGPAASFTHSAAAKAFP....KEEMIAKSTIPDCIMAIEKEDVDVAVVPIENTIEGSVNITLDYLFH.FSS
KVGYLGPIGSFTYSATLAAFP....EATLMPYASIPACLKAIEQQEVAWSIIPIENTIEGTVNASIDYLYH.QAQ
KIAYLGPRGSFCSVVAETAFV....SEELFAYDSILDVIEAYDEGKCDFALVPIENSTEGTVNMSIDKIFH.DSK
KIAYLGPKGSFSHHVVQTAFP....HEELQAFANITDVIKAYEQGLVNYSVVPVENSIEGSVHETLDYLFH.QAH
RIAFQGEFGANSDMACR.DM...FPDMEPLPCPTFEDAFNAIENGEADLGMIPIENTLAGRVADIHHLLP..ESR
RISFQGDYGANSDMACR.DM...FPSMEPLPCQTFEDAFLAVENGEADLAMIPIENTIAGRVADIHHLLP..ESR
RISFQGEAGANSDTACR.NM...FPDMEPLPCPTFEDAFNAVETGAADLAMIPIENTLAGRVADIHYLLP..LAD
RISFQGEPGANSDTACR.NV...YPSMEPLPCPTFEDAFNAVETGKADLAMIPIENTIAGRVADIHHLLP..ESR
KIAFQGEPGANSHIAIV.EA...YPDAEPMPCATFEDALSAISSGEADLGMIPIENSVAGRVADIHHLLP..ASG
KIAFQGEPGANSHIAIS.DA...YPTAEAMPCATFEDALSAISSGEADLGMIPIENSVAGRVADIHHLLP..TSK
SIAFQGEPGAYSHLACR.NA...YPGMQPLPCATFEDTFAAVREGRARYAMIPIDNSVAGRVADVHHLMP..YAG
VVAFQGAHGAYSEQACR.EK...LPGYQSRPYKTFEDIFIAVEQGDAELGMLPVENSMAGVVSDSYDLLA..VHN
LIAYQGEPGAYSEIAAL.......RFGEPLPCESFDDVFSAVTEQKADYAVIPIENSLGGSIHQNYDLLL..RRP
AVAFQGNPGSYGEIAALNAL...PQVRETLGYPTFHEVARAVENGEADYGVLPVENSLMGAIHQSIDLLT..ETE
RIAFLGPKGSYSHLAARQYAARHFEQFIESGCAKFADIFNQVETGQADYAVVPIENTSSGAINDVYDLLQ..HTS
RIAFLGPKGSYSHLAARQYAARHFEQFIESGCAKFTDIFHQVETGQADYAVVPIENTSSGAINDVYDLLQ..HTS
RIAFLGPKGSYSHLAARNYASRHFDSMVECGCLKFHDIIKQVENGVADYAVMPIENTSSGSINDVYDLLQ..QTS
HIAFLGKRGSYSNLAARNYAARYQKQFVELGCQSFEQVFEKVQTGEADFGVLPLENTTSGAINEVYDLLQ..HTD
RVAFLGAKGSYSHLATREYFSRKNTELIELNCDHFKEVARTVESGHADYGVLPIENTSSGSINEVYDLLQ..HTT
KVAYLGPEGTFTQAAALKHFG...NAVISTPMAAIDEVFREVAAGAVNFGVVPVENSTEGAVNHTLDSFL..EHD
RVAYLGPEGTFSQAAALKHFG...HSVISKPMAAIDEVFREVVAGAVNFGVVPVENSTEGAVNHTLDSFL..EHD
KVGYLGPKGTFSEEAVFKYIEG.MKECEAIEFATIQDVVKSVAEGTCDEGILPVENSIEGSVNVSLDLLINDAEG
QLYYLGPKGTFSYLACRQYFS..ENEATFQPKSNLFEVIKAVADDDTSIGVVPIENSIEGTINIVADALA..QQD
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LSIVGEITVPIQQHLLVHPQYADVWEEVYAVHSHPHAIAQCHKFLNEELKGVTARDMTSTSAAAQYVKEHPEEKI
LPIVGEMTLPIHQHLLVHPSRENAWKELDKIYSHSHAIAQCHKFLHRHFPSVPYEYANSTGAAAKFVSDHPELNI
LEIVADIVVPISQHFLVHPNQRD..NEIKKILSHPHAVAQCHEFLRSSYPGVEIEYMTSTAAAAQWVADHPNEPV
VPVVAEIVLPIAQHLMVHPAHKATWKSVQKVMSHPQALAQCHTFLQAELYGVEREVTPSTAYAAKWVSNNPTELV
VPVVAEIVLPIAQHLMVHPAHVSAWKSVQKVMSHPQALAQCHTFLQAELYGVEREVTPSTAYAAKWVSNNPTELV
LPVQAELVLPIQQQLMVAKENQAIWQQSQKILSHPQALAQSQMFLEKNFPEAILEATPSTAYAAKYIAEHPELPF
ATVVAEFVLPISQNLLALSKE....GKIEHIYSHPQALAQTRNYLREHYPQAKVEITDSTSAAAEFVKNHPDLPI
IQAVAEIVQPIHQQLMVVPGH....TKIEKIFSHPQALAQGKKFIDEQYPEAQIEVTASTAYAARFISEHPDQPF
LHIIGEYFMPIRFQLMVVPGVTK..DEIRTVHSHIHALGQCRKIIRSN..GWKPVIAGDTAGSARLVSEKGDRSM
LHIVGEYFMPIRFQLMVLPGVGR..EEIRTVHSHIHALGQCRKIVRAN..GWKPVVAGDTAGAAKLVKEVGDRSM
MHIVGEYFLPIHFQLMVLPGVRR..EEIKTVHSHIHALGQCRNVIRQN..GWKGVIAGDTAGAARLVADVKDRSM
MHIVGEYFLPIHFQLMVLPGVKR..DEIKTVHSHIHALGQCRKYIRKN..GWKAVVAGDTAGAAKMISEVKDRTM
LFIIGEWFLPVRHQLMAVKGAKI..SDIKSVESHVHALGQCRRIIRKL..GIKPIVHADTAGSARDISERKDKTV
LFIVGEWFLPIRHQLVAVPGAKL..EDIKTVESHVHALGQCRRIIRKF..GLKPIVAGDTAGSARIIAERGDKTC
LHIIAEHFERISHHLLAVPGATL..ATIKSVKSHVHALGQCRNLIREL..GLKVIVGTDTAGAAAELAERQDPTM
LHIIGEYYLPVRHCLMAHQGVNV..ERIHTVYSHPQALAQCHSFIKRH..GWNRVAVYDTAGAAAALKEEHREGE
VVILAETFVKVEHCLLGLPGASV..ETATKAMSHPQALVQCHNFFATHP.QIRAEAAYDTAGSAKMVAESRDKSA
LHVTGEVVVRVSHCLMALPGVEM..ADIRKVGSQQPALDQCTHLIREH..GWQPLAKHDTAGSAKDLAERGARDE
LSIVGEMTLTIDHCLLVSGTTDL..SAINTVYSHPQPFQQCSKFLNRYP.HWKIEYTESTSAAMEKVAQAKSPHV
LSIVGEMTVTIDHCVLVSGATDL..NTIETVYSHPQPFQQCSKFLSRYP.HWKIDYTESTSAAMEKVAQANSPRV
LSIVGELTLPIDHCVLVNGPTDL..QQIETVYSHPQPFQQCSQFINRFP.HWKIEYTESTAAAMEKVAALNSPKV
LSLVGELAYPIKHCVLVNDKTDL..NQIDTLYSHPQVIQQCSQFIHSLD.RVHIEYCESSSHAMQLVASLNKPNI
LYIVGELTQPIEHCLVATQEIRL..EDLKVLYSHPQPHQQCSEFLSRLK.GVKLESCASTADAMKKVQELNRADV
MVICGEVELRIHHHLLVGETTKT..DNITRIYSHAQSLAQCRKWLDSH..YPSVERVAVSSNADAAKRVKSEWNS
IVICGEVELRIHHHLLVGETTKT..DRITRIYSHAQSLAQCRKWLDAH..YPNVERVAVSSNADAAKRVKSEWNS
ILVRGEVIISISQCLICDDFIDF..KDVHCILSHPQALAQCREYILNN..FPTAEVKTTESTVKALLGVNAKKGI
VFAHGEIRLDINFALYGNGTDSI..SDIKKVYSIAPAISQTTNYIHQH..QFDYDYVDSTIQSLTKIEN....GV
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AAIANEAAAEKYGLTIVRRGIHTHKNNHTRFLVLHKKKKAILPNNGENRGE.KTTLMITLP.ADYAGALYQVLSA
GVIANDMAASTYELKIVKRDIQDYRDNHTRFVILSPDENISFEVNSKLSSRPKTTLMVMLPQDDQSGALHRVLSA
AAIANEQAATSYQLDMLEKDIHDYDENRTRFAVLAKGKLSLPPYQVEPYTK.KTTMMVTLS.SDFSGALHQVLSA
AAIAPRMAASEYGLEIVQENAQDLELNQTRFFVLSRKPVSILLPKEE...E.KTSISVILP.NNMPGALHKVLST
AAIAPRMAANEYGLEIVKENAQDLELNQTRFFVLSRKPVSILLPKEE...E.KTSISVILP.NNMPGALHKVLST
AAIAPKLSAEMYDLTIVEKNIQDLSVNQTRFWVLGSENLAISFPLSE...K.KITLAITMP.SNVPGSLHKVLSV
AAVANSYAAKMYDLEIVAKNIQDLAGNSTRFWLLGKEKKSFDLLKTG...E.KVSLALTLP.DNLPGALHKAISV
AAVAPRSSAEEYGLELIAEDIQEMEANFTRFWVLGAEKPSIPLQAQT...E.KMSLALTLP.DNLPGALYKALST
AALAPRLAADLYGLDILAENVEDSENNVTRFVVLSRDENWAKRQ....SSDEIVVTTFVFNVRNIPAALYKAMGG
AALAPRLAADLYGLDIIAENVEDTDSNVTRFVVLSREESRVART....SKDELIITTFVFNVRNIPAALYKAMGG
AALAPRLAADLYGLDILEENVEDSENNVTRFVVLSKNKQWAARP....ENDERIVTTFVFRVRNVPAALYKALGG
AALSPALAATLYGLDIIEENVEDTDSNVTRFVVLTKSKQWAERP....SPDVKMMTTFIFRVRNVPAALYKAMGG
AAIASRLAAKIYGLDILAEDIEDEAHNTTRFVVLAREPKWAAQG....SGP..LVTTFVFRVRNLPAALYKALGG
AAISSRLAAKIYGLDILAEDIEDEAHNTTRFVVLAREPRWAVQG....SGK..LVTTFVFRVRNLPAALYKALGG
AAIASELAAEAYGLVSLKAGIEDAEHNTTRFVVLAREA.LEPNP....NQP..CVTTFVFRVRNVAAALYKALGG
AAIASALAAELYGLDLLAEQIQDSANNTTRFLIIAKDG.IIPMP....NVG..CKISLLFEVRHIPAALYKCLGG
LAIASKRAGELYGLDILKENLADEEWNITRFFCIAHENNPDISHLKVRPDVARQKTSIVFALPNEQGSLFRALAT
AAIASRRAAELYGLNILQTGVEDEPFNFTRFMVLSR.HAP.......EPSDAPHKTSLIFAVRHTPGFLLETLG.
AALGSEAGGTLYGLQVLERIEANQRQNFTRFVVLARKAIN.......VSDQVPAKTTLLMATGQQAGALVEALLV
AALGSEAGGMLHGLQVLERIAANQTQNITRFLVLARKAIN.......VSDQVPAKTTLLIATGQQAGALVEALLV
AALGSEAGGELYQLQVLERNLANQQQNHTRFIVLARKAIE.......VSDQVPAKTTLIMATGQQAGALVDALLV
AALGNEDGGKLYGLSVLKTNIANQENNITRFIVVAKEPRE.......VSSQIPTKTLLLMTTSQQAGALVDALLV
AAIGNSASGKLYGLQPIQGNIANQTENHTRFIVVARKPVD.......VSPQIPAKTTLIMSTSQEAGSLVSTLLV
AAIAGDMAASLYDLSKLHEKIEDRPDNSTRFLIIGNQEVP.........PTGDDKTSIIVSMRNKPGALHELLVP
AAIAGDMAAQLYGLSKLAEKIEDRPVNSTRFLIIGSQEVP.........PTGDDKTSIIVSMRNKPGALHELLMP
VAIGPERAAWLYNLKILEKDVQDIKENYTRFLVIAKRDSD.........YTGEDKTSIVFSVPNVPGSLYRALGV
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FAWRKLNLSKIESRPMKTGLGNYFFLIDVDKAYDEV.LLPGVTMELEALGFSVTVLGSYSSYWL..........
FSWRNLNLSKIESRPTKTGLGHYFFIIDIEKAFDDV.LIPGAMQELEALGCKVRLLGAYQSYQL..........
FAWRKLNLTKIESRPMKTGLGNYFFIIDVDCEADDV.LIPGVMQELEALGCGVELLGSYPCFFHTSLKLTEASS
FAWRDIDLSKIESRPLKTSLGEYFFLIDVLSEGKET.LVTNALDEIRLLGGKANKLGTYHVHRLQTT.......
FAWRDIDLSKIESRPLKTSLGEYFFLIDVLSEGKEV.LVTNALDEITLLGGTANKLGTYHVHRLQTN.......
FSWRGINLSKIESRPLKTKLGEYFFLMDLVKDQPEK.LIEAALTELELIGAEIKILGDYPIYVLSTL.......
FAWRDIDMTKIESRPLRTRLGQYFFNIDLVNNEKNNLKIPYALEELSGLGVKVRLLGNYAVYSLGEG.......
FAWRGIDLTKIESRPLKTALGEYFFIIDVDYTDKD..LVHFAQKELEAIGIQYKILGAYPIYPISDHGKERR..
FATNGINMTKLESYQLGGKFVATQFYADIEGHPDDE.PVRHALDELRFFSEKVRILGVYNGHAMRGKLNQS...
FATNGINMTKLESYQLGGKFVATQFYADIEGHPDDI.GVRHAMDELRFFSENVRILGTYPAHPMRGVL......
FATNGVNMTKLESYQLGGRFIATQFYADIEGHPEER.SVQLALEELRFFTKEVRILGVYKGSDIRGTQLLAAE.
FATNGINMTKLESYQLG.AFTATLFYADIEGHPDDP.LVKLALDELRFFSREVRILGVYPASESR.EQWKVAD.
FATNGVNMTKLESYMVDGNFFATQFYADVDGHPEDK.GLAFAIEELKFFSREFRIVGVYPGHPFRATFSETQQD
FATNGVNMTKLESYMVDGNFFATQFYADVEGHPEDR.NLAFALDELKFFSREFRIVGVYPGHPFRATFSER...
FATNGINMTRLESYMVGGEFAATQFYADVEGHPTQR.NLRLALEELDFFSHEVRILGVYPRHPFRMKQQGGGQ.
FATNGINLTRLESRPVAGRDWSYHFYLDFQGRMDQV.NVQQALEELKFYTHNMKVLGCYP.ESLRPESQGAL..
FALRGIDLTKIESRPSRKKAFEYLFYADFIGHREDQ.NVHNALENLREFATMVKVLGSYGVVNP..........
.ELRGLNLSRIESRPRRDRAWSYLMYVDIEGKASDP.QVAQALAGILVKASYAKIIGSYPAAQGTVQ.......
LRNHSLIMTRLESRPIHGNPWEEMFYLDIQANLESA.EMQKALKELGEITRSMKVLGCYPSENVVPVDPT....
LRNHNLIMTKLESRPIHGNPWEEMFYLDIQANLESQ.VMQSALKELGEITRSMKVLGCYPSENVVPVEPA....
LRQHNLIMSKLESRPINGNPWEEMFYIDVQGNLQSE.RMQQALQELQTMTRSLKVLGCYPSENVVPAEPGR...
FKKHQINMTKLESRPIYGKPWEEMFYLEIEANIHHP.DTKQALEELKNYSNYLKILGCYPSEIVKPVSV.....
LQRYGINMTKLESRPIMGNPWEEMFYVDLEAHIDSD.EMQQALAELTQLTRHLKVLGCYPSENVKPTQVKFI..
FHNNGIDLTRIETRPSRSGKWTYVFFIDFVGHHKEP.LIKDVLEKIGQEAVALKVLGSYPKAVL..........
FHSNGIDLTRIETRPSRSGKWTYVFFIDCMGHHQDP.LIKNVLEKIGHEAVALKVLGSYPKAVL..........
FAEKNINMTKIESRPSRKKFGEYVFWVDIEGHRKEE.RIKEALEDLKIKADFLKVIGSYPKFKMGK........
FALFNINLSWIESRPLKTQLGMYRFFVQADSAITTD..IKKVIAILETLDFKVEMIGAFN..............
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RVGYLGPEATFTNMAVSRFFP....EAEHVPYRTIPDCMDAAANGNVDYAVVPLENAIEGSVNITVDYLVH.EQP
KVGYLGPAATFTHLAVSSCFQN...GAEHVAYRTIPECIDAAVAGEVDFAFVPLENALEGSVNLTIDYLIH.EQP
KIGYLGPRGTFTEMAVQTLFDD...KNVLKPYRTIPDCMDSVANGDMDAAVVPVENAIEGSVNVTLDYLIH.KQR
KIAYLGPAASFTHAAAAKAFP....KEEMVAKSTIPDCIMAIEKEDVDVAVVPIENTIEGSVNITLDYLFH.FSS
KIAYLGPAASFTHSAAAKAFP....KEEMIAKSTIPDCIMAIEKEDVDVAVVPIENTIEGSVNITLDYLFH.FSS
KVGYLGPIGSFTYSATLAAFP....EATLMPYASIPACLKAIEQQEVAWSIIPIENTIEGTVNASIDYLYH.QAQ
KIAYLGPRGSFCSVVAETAFV....SEELFAYDSILDVIEAYDEGKCDFALVPIENSTEGTVNMSIDKIFH.DSK
KIAYLGPKGSFSHHVVQTAFP....HEELQAFANITDVIKAYEQGLVNYSVVPVENSIEGSVHETLDYLFH.QAH
RIAFQGEFGANSDMACR.DM...FPDMEPLPCPTFEDAFNAIENGEADLGMIPIENTLAGRVADIHHLLP..ESR
RISFQGDYGANSDMACR.DM...FPSMEPLPCQTFEDAFLAVENGEADLAMIPIENTIAGRVADIHHLLP..ESR
RISFQGEAGANSDTACR.NM...FPDMEPLPCPTFEDAFNAVETGAADLAMIPIENTLAGRVADIHYLLP..LAD
RISFQGEPGANSDTACR.NV...YPSMEPLPCPTFEDAFNAVETGKADLAMIPIENTIAGRVADIHHLLP..ESR
KIAFQGEPGANSHIAIV.EA...YPDAEPMPCATFEDALSAISSGEADLGMIPIENSVAGRVADIHHLLP..ASG
KIAFQGEPGANSHIAIS.DA...YPTAEAMPCATFEDALSAISSGEADLGMIPIENSVAGRVADIHHLLP..TSK
SIAFQGEPGAYSHLACR.NA...YPGMQPLPCATFEDTFAAVREGRARYAMIPIDNSVAGRVADVHHLMP..YAG
VVAFQGAHGAYSEQACR.EK...LPGYQSRPYKTFEDIFIAVEQGDAELGMLPVENSMAGVVSDSYDLLA..VHN
LIAYQGEPGAYSEIAAL.......RFGEPLPCESFDDVFSAVTEQKADYAVIPIENSLGGSIHQNYDLLL..RRP
AVAFQGNPGSYGEIAALNAL...PQVRETLGYPTFHEVARAVENGEADYGVLPVENSLMGAIHQSIDLLT..ETE
RIAFLGPKGSYSHLAARQYAARHFEQFIESGCAKFADIFNQVETGQADYAVVPIENTSSGAINDVYDLLQ..HTS
RIAFLGPKGSYSHLAARQYAARHFEQFIESGCAKFTDIFHQVETGQADYAVVPIENTSSGAINDVYDLLQ..HTS
RIAFLGPKGSYSHLAARNYASRHFDSMVECGCLKFHDIIKQVENGVADYAVMPIENTSSGSINDVYDLLQ..QTS
HIAFLGKRGSYSNLAARNYAARYQKQFVELGCQSFEQVFEKVQTGEADFGVLPLENTTSGAINEVYDLLQ..HTD
RVAFLGAKGSYSHLATREYFSRKNTELIELNCDHFKEVARTVESGHADYGVLPIENTSSGSINEVYDLLQ..HTT
KVAYLGPEGTFTQAAALKHFG...NAVISTPMAAIDEVFREVAAGAVNFGVVPVENSTEGAVNHTLDSFL..EHD
RVAYLGPEGTFSQAAALKHFG...HSVISKPMAAIDEVFREVVAGAVNFGVVPVENSTEGAVNHTLDSFL..EHD
KVGYLGPKGTFSEEAVFKYIEG.MKECEAIEFATIQDVVKSVAEGTCDEGILPVENSIEGSVNVSLDLLINDAEG
QLYYLGPKGTFSYLACRQYFS..ENEATFQPKSNLFEVIKAVADDDTSIGVVPIENSIEGTINIVADALA..QQD
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LSIVGEITVPIQQHLLVHPQYADVWEEVYAVHSHPHAIAQCHKFLNEELKGVTARDMTSTSAAAQYVKEHPEEKI
LPIVGEMTLPIHQHLLVHPSRENAWKELDKIYSHSHAIAQCHKFLHRHFPSVPYEYANSTGAAAKFVSDHPELNI
LEIVADIVVPISQHFLVHPNQRD..NEIKKILSHPHAVAQCHEFLRSSYPGVEIEYMTSTAAAAQWVADHPNEPV
VPVVAEIVLPIAQHLMVHPAHKATWKSVQKVMSHPQALAQCHTFLQAELYGVEREVTPSTAYAAKWVSNNPTELV
VPVVAEIVLPIAQHLMVHPAHVSAWKSVQKVMSHPQALAQCHTFLQAELYGVEREVTPSTAYAAKWVSNNPTELV
LPVQAELVLPIQQQLMVAKENQAIWQQSQKILSHPQALAQSQMFLEKNFPEAILEATPSTAYAAKYIAEHPELPF
ATVVAEFVLPISQNLLALSKE....GKIEHIYSHPQALAQTRNYLREHYPQAKVEITDSTSAAAEFVKNHPDLPI
IQAVAEIVQPIHQQLMVVPGH....TKIEKIFSHPQALAQGKKFIDEQYPEAQIEVTASTAYAARFISEHPDQPF
LHIIGEYFMPIRFQLMVVPGVTK..DEIRTVHSHIHALGQCRKIIRSN..GWKPVIAGDTAGSARLVSEKGDRSM
LHIVGEYFMPIRFQLMVLPGVGR..EEIRTVHSHIHALGQCRKIVRAN..GWKPVVAGDTAGAAKLVKEVGDRSM
MHIVGEYFLPIHFQLMVLPGVRR..EEIKTVHSHIHALGQCRNVIRQN..GWKGVIAGDTAGAARLVADVKDRSM
MHIVGEYFLPIHFQLMVLPGVKR..DEIKTVHSHIHALGQCRKYIRKN..GWKAVVAGDTAGAAKMISEVKDRTM
LFIIGEWFLPVRHQLMAVKGAKI..SDIKSVESHVHALGQCRRIIRKL..GIKPIVHADTAGSARDISERKDKTV
LFIVGEWFLPIRHQLVAVPGAKL..EDIKTVESHVHALGQCRRIIRKF..GLKPIVAGDTAGSARIIAERGDKTC
LHIIAEHFERISHHLLAVPGATL..ATIKSVKSHVHALGQCRNLIREL..GLKVIVGTDTAGAAAELAERQDPTM
LHIIGEYYLPVRHCLMAHQGVNV..ERIHTVYSHPQALAQCHSFIKRH..GWNRVAVYDTAGAAAALKEEHREGE
VVILAETFVKVEHCLLGLPGASV..ETATKAMSHPQALVQCHNFFATHP.QIRAEAAYDTAGSAKMVAESRDKSA
LHVTGEVVVRVSHCLMALPGVEM..ADIRKVGSQQPALDQCTHLIREH..GWQPLAKHDTAGSAKDLAERGARDE
LSIVGEMTLTIDHCLLVSGTTDL..SAINTVYSHPQPFQQCSKFLNRYP.HWKIEYTESTSAAMEKVAQAKSPHV
LSIVGEMTVTIDHCVLVSGATDL..NTIETVYSHPQPFQQCSKFLSRYP.HWKIDYTESTSAAMEKVAQANSPRV
LSIVGELTLPIDHCVLVNGPTDL..QQIETVYSHPQPFQQCSQFINRFP.HWKIEYTESTAAAMEKVAALNSPKV
LSLVGELAYPIKHCVLVNDKTDL..NQIDTLYSHPQVIQQCSQFIHSLD.RVHIEYCESSSHAMQLVASLNKPNI
LYIVGELTQPIEHCLVATQEIRL..EDLKVLYSHPQPHQQCSEFLSRLK.GVKLESCASTADAMKKVQELNRADV
MVICGEVELRIHHHLLVGETTKT..DNITRIYSHAQSLAQCRKWLDSH..YPSVERVAVSSNADAAKRVKSEWNS
IVICGEVELRIHHHLLVGETTKT..DRITRIYSHAQSLAQCRKWLDAH..YPNVERVAVSSNADAAKRVKSEWNS
ILVRGEVIISISQCLICDDFIDF..KDVHCILSHPQALAQCREYILNN..FPTAEVKTTESTVKALLGVNAKKGI
VFAHGEIRLDINFALYGNGTDSI..SDIKKVYSIAPAISQTTNYIHQH..QFDYDYVDSTIQSLTKIEN....GV
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AAIANEAAAEKYGLTIVRRGIHTHKNNHTRFLVLHKKKKAILPNNGENRGE.KTTLMITLP.ADYAGALYQVLSA
GVIANDMAASTYELKIVKRDIQDYRDNHTRFVILSPDENISFEVNSKLSSRPKTTLMVMLPQDDQSGALHRVLSA
AAIANEQAATSYQLDMLEKDIHDYDENRTRFAVLAKGKLSLPPYQVEPYTK.KTTMMVTLS.SDFSGALHQVLSA
AAIAPRMAASEYGLEIVQENAQDLELNQTRFFVLSRKPVSILLPKEE...E.KTSISVILP.NNMPGALHKVLST
AAIAPRMAANEYGLEIVKENAQDLELNQTRFFVLSRKPVSILLPKEE...E.KTSISVILP.NNMPGALHKVLST
AAIAPKLSAEMYDLTIVEKNIQDLSVNQTRFWVLGSENLAISFPLSE...K.KITLAITMP.SNVPGSLHKVLSV
AAVANSYAAKMYDLEIVAKNIQDLAGNSTRFWLLGKEKKSFDLLKTG...E.KVSLALTLP.DNLPGALHKAISV
AAVAPRSSAEEYGLELIAEDIQEMEANFTRFWVLGAEKPSIPLQAQT...E.KMSLALTLP.DNLPGALYKALST
AALAPRLAADLYGLDILAENVEDSENNVTRFVVLSRDENWAKRQ....SSDEIVVTTFVFNVRNIPAALYKAMGG
AALAPRLAADLYGLDIIAENVEDTDSNVTRFVVLSREESRVART....SKDELIITTFVFNVRNIPAALYKAMGG
AALAPRLAADLYGLDILEENVEDSENNVTRFVVLSKNKQWAARP....ENDERIVTTFVFRVRNVPAALYKALGG
AALSPALAATLYGLDIIEENVEDTDSNVTRFVVLTKSKQWAERP....SPDVKMMTTFIFRVRNVPAALYKAMGG
AAIASRLAAKIYGLDILAEDIEDEAHNTTRFVVLAREPKWAAQG....SGP..LVTTFVFRVRNLPAALYKALGG
AAISSRLAAKIYGLDILAEDIEDEAHNTTRFVVLAREPRWAVQG....SGK..LVTTFVFRVRNLPAALYKALGG
AAIASELAAEAYGLVSLKAGIEDAEHNTTRFVVLAREA.LEPNP....NQP..CVTTFVFRVRNVAAALYKALGG
AAIASALAAELYGLDLLAEQIQDSANNTTRFLIIAKDG.IIPMP....NVG..CKISLLFEVRHIPAALYKCLGG
LAIASKRAGELYGLDILKENLADEEWNITRFFCIAHENNPDISHLKVRPDVARQKTSIVFALPNEQGSLFRALAT
AAIASRRAAELYGLNILQTGVEDEPFNFTRFMVLSR.HAP.......EPSDAPHKTSLIFAVRHTPGFLLETLG.
AALGSEAGGTLYGLQVLERIEANQRQNFTRFVVLARKAIN.......VSDQVPAKTTLLMATGQQAGALVEALLV
AALGSEAGGMLHGLQVLERIAANQTQNITRFLVLARKAIN.......VSDQVPAKTTLLIATGQQAGALVEALLV
AALGSEAGGELYQLQVLERNLANQQQNHTRFIVLARKAIE.......VSDQVPAKTTLIMATGQQAGALVDALLV
AALGNEDGGKLYGLSVLKTNIANQENNITRFIVVAKEPRE.......VSSQIPTKTLLLMTTSQQAGALVDALLV
AAIGNSASGKLYGLQPIQGNIANQTENHTRFIVVARKPVD.......VSPQIPAKTTLIMSTSQEAGSLVSTLLV
AAIAGDMAASLYDLSKLHEKIEDRPDNSTRFLIIGNQEVP.........PTGDDKTSIIVSMRNKPGALHELLVP
AAIAGDMAAQLYGLSKLAEKIEDRPVNSTRFLIIGSQEVP.........PTGDDKTSIIVSMRNKPGALHELLMP
VAIGPERAAWLYNLKILEKDVQDIKENYTRFLVIAKRDSD.........YTGEDKTSIVFSVPNVPGSLYRALGV
AAIAPLGSGEAYGFTPIDTHIEDYPHNVTRFLVIKNQQQFD........QNATSLMFLITPMHDKPGLLASVLNT
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FAWRKLNLSKIESRPMKTGLGNYFFLIDVDKAYDEV.LLPGVTMELEALGFSVTVLGSYSSYWL..........
FSWRNLNLSKIESRPTKTGLGHYFFIIDIEKAFDDV.LIPGAMQELEALGCKVRLLGAYQSYQL..........
FAWRKLNLTKIESRPMKTGLGNYFFIIDVDCEADDV.LIPGVMQELEALGCGVELLGSYPCFFHTSLKLTEASS
FAWRDIDLSKIESRPLKTSLGEYFFLIDVLSEGKET.LVTNALDEIRLLGGKANKLGTYHVHRLQTT.......
FAWRDIDLSKIESRPLKTSLGEYFFLIDVLSEGKEV.LVTNALDEITLLGGTANKLGTYHVHRLQTN.......
FSWRGINLSKIESRPLKTKLGEYFFLMDLVKDQPEK.LIEAALTELELIGAEIKILGDYPIYVLSTL.......
FAWRDIDMTKIESRPLRTRLGQYFFNIDLVNNEKNNLKIPYALEELSGLGVKVRLLGNYAVYSLGEG.......
FAWRGIDLTKIESRPLKTALGEYFFIIDVDYTDKD..LVHFAQKELEAIGIQYKILGAYPIYPISDHGKERR..
FATNGINMTKLESYQLGGKFVATQFYADIEGHPDDE.PVRHALDELRFFSEKVRILGVYNGHAMRGKLNQS...
FATNGINMTKLESYQLGGKFVATQFYADIEGHPDDI.GVRHAMDELRFFSENVRILGTYPAHPMRGVL......
FATNGVNMTKLESYQLGGRFIATQFYADIEGHPEER.SVQLALEELRFFTKEVRILGVYKGSDIRGTQLLAAE.
FATNGINMTKLESYQLG.AFTATLFYADIEGHPDDP.LVKLALDELRFFSREVRILGVYPASESR.EQWKVAD.
FATNGVNMTKLESYMVDGNFFATQFYADVDGHPEDK.GLAFAIEELKFFSREFRIVGVYPGHPFRATFSETQQD
FATNGVNMTKLESYMVDGNFFATQFYADVEGHPEDR.NLAFALDELKFFSREFRIVGVYPGHPFRATFSER...
FATNGINMTRLESYMVGGEFAATQFYADVEGHPTQR.NLRLALEELDFFSHEVRILGVYPRHPFRMKQQGGGQ.
FATNGINLTRLESRPVAGRDWSYHFYLDFQGRMDQV.NVQQALEELKFYTHNMKVLGCYP.ESLRPESQGAL..
FALRGIDLTKIESRPSRKKAFEYLFYADFIGHREDQ.NVHNALENLREFATMVKVLGSYGVVNP..........
.ELRGLNLSRIESRPRRDRAWSYLMYVDIEGKASDP.QVAQALAGILVKASYAKIIGSYPAAQGTVQ.......
LRNHSLIMTRLESRPIHGNPWEEMFYLDIQANLESA.EMQKALKELGEITRSMKVLGCYPSENVVPVDPT....
LRNHNLIMTKLESRPIHGNPWEEMFYLDIQANLESQ.VMQSALKELGEITRSMKVLGCYPSENVVPVEPA....
LRQHNLIMSKLESRPINGNPWEEMFYIDVQGNLQSE.RMQQALQELQTMTRSLKVLGCYPSENVVPAEPGR...
FKKHQINMTKLESRPIYGKPWEEMFYLEIEANIHHP.DTKQALEELKNYSNYLKILGCYPSEIVKPVSV.....
LQRYGINMTKLESRPIMGNPWEEMFYVDLEAHIDSD.EMQQALAELTQLTRHLKVLGCYPSENVKPTQVKFI..
FHNNGIDLTRIETRPSRSGKWTYVFFIDFVGHHKEP.LIKDVLEKIGQEAVALKVLGSYPKAVL..........
FHSNGIDLTRIETRPSRSGKWTYVFFIDCMGHHQDP.LIKNVLEKIGHEAVALKVLGSYPKAVL..........
FAEKNINMTKIESRPSRKKFGEYVFWVDIEGHRKEE.RIKEALEDLKIKADFLKVIGSYPKFKMGK........
FALFNINLSWIESRPLKTQLGMYRFFVQADSAITTD..IKKVIAILETLDFKVEMIGAFN..............
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RVGYLGPEATFTNMAVSRFFP....EAEHVPYRTIPDCMDAAANGNVDYAVVPLENAIEGSVNITVDYLVH.EQP
KVGYLGPAATFTHLAVSSCFQN...GAEHVAYRTIPECIDAAVAGEVDFAFVPLENALEGSVNLTIDYLIH.EQP
KIGYLGPRGTFTEMAVQTLFDD...KNVLKPYRTIPDCMDSVANGDMDAAVVPVENAIEGSVNVTLDYLIH.KQR
KIAYLGPAASFTHAAAAKAFP....KEEMVAKSTIPDCIMAIEKEDVDVAVVPIENTIEGSVNITLDYLFH.FSS
KIAYLGPAASFTHSAAAKAFP....KEEMIAKSTIPDCIMAIEKEDVDVAVVPIENTIEGSVNITLDYLFH.FSS
KVGYLGPIGSFTYSATLAAFP....EATLMPYASIPACLKAIEQQEVAWSIIPIENTIEGTVNASIDYLYH.QAQ
KIAYLGPRGSFCSVVAETAFV....SEELFAYDSILDVIEAYDEGKCDFALVPIENSTEGTVNMSIDKIFH.DSK
KIAYLGPKGSFSHHVVQTAFP....HEELQAFANITDVIKAYEQGLVNYSVVPVENSIEGSVHETLDYLFH.QAH
RIAFQGEFGANSDMACR.DM...FPDMEPLPCPTFEDAFNAIENGEADLGMIPIENTLAGRVADIHHLLP..ESR
RISFQGDYGANSDMACR.DM...FPSMEPLPCQTFEDAFLAVENGEADLAMIPIENTIAGRVADIHHLLP..ESR
RISFQGEAGANSDTACR.NM...FPDMEPLPCPTFEDAFNAVETGAADLAMIPIENTLAGRVADIHYLLP..LAD
RISFQGEPGANSDTACR.NV...YPSMEPLPCPTFEDAFNAVETGKADLAMIPIENTIAGRVADIHHLLP..ESR
KIAFQGEPGANSHIAIV.EA...YPDAEPMPCATFEDALSAISSGEADLGMIPIENSVAGRVADIHHLLP..ASG
KIAFQGEPGANSHIAIS.DA...YPTAEAMPCATFEDALSAISSGEADLGMIPIENSVAGRVADIHHLLP..TSK
SIAFQGEPGAYSHLACR.NA...YPGMQPLPCATFEDTFAAVREGRARYAMIPIDNSVAGRVADVHHLMP..YAG
VVAFQGAHGAYSEQACR.EK...LPGYQSRPYKTFEDIFIAVEQGDAELGMLPVENSMAGVVSDSYDLLA..VHN
LIAYQGEPGAYSEIAAL.......RFGEPLPCESFDDVFSAVTEQKADYAVIPIENSLGGSIHQNYDLLL..RRP
AVAFQGNPGSYGEIAALNAL...PQVRETLGYPTFHEVARAVENGEADYGVLPVENSLMGAIHQSIDLLT..ETE
RIAFLGPKGSYSHLAARQYAARHFEQFIESGCAKFADIFNQVETGQADYAVVPIENTSSGAINDVYDLLQ..HTS
RIAFLGPKGSYSHLAARQYAARHFEQFIESGCAKFTDIFHQVETGQADYAVVPIENTSSGAINDVYDLLQ..HTS
RIAFLGPKGSYSHLAARNYASRHFDSMVECGCLKFHDIIKQVENGVADYAVMPIENTSSGSINDVYDLLQ..QTS
HIAFLGKRGSYSNLAARNYAARYQKQFVELGCQSFEQVFEKVQTGEADFGVLPLENTTSGAINEVYDLLQ..HTD
RVAFLGAKGSYSHLATREYFSRKNTELIELNCDHFKEVARTVESGHADYGVLPIENTSSGSINEVYDLLQ..HTT
KVAYLGPEGTFTQAAALKHFG...NAVISTPMAAIDEVFREVAAGAVNFGVVPVENSTEGAVNHTLDSFL..EHD
RVAYLGPEGTFSQAAALKHFG...HSVISKPMAAIDEVFREVVAGAVNFGVVPVENSTEGAVNHTLDSFL..EHD
KVGYLGPKGTFSEEAVFKYIEG.MKECEAIEFATIQDVVKSVAEGTCDEGILPVENSIEGSVNVSLDLLINDAEG
QLYYLGPKGTFSYLACRQYFS..ENEATFQPKSNLFEVIKAVADDDTSIGVVPIENSIEGTINIVADALA..QQD
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LSIVGEITVPIQQHLLVHPQYADVWEEVYAVHSHPHAIAQCHKFLNEELKGVTARDMTSTSAAAQYVKEHPEEKI
LPIVGEMTLPIHQHLLVHPSRENAWKELDKIYSHSHAIAQCHKFLHRHFPSVPYEYANSTGAAAKFVSDHPELNI
LEIVADIVVPISQHFLVHPNQRD..NEIKKILSHPHAVAQCHEFLRSSYPGVEIEYMTSTAAAAQWVADHPNEPV
VPVVAEIVLPIAQHLMVHPAHKATWKSVQKVMSHPQALAQCHTFLQAELYGVEREVTPSTAYAAKWVSNNPTELV
VPVVAEIVLPIAQHLMVHPAHVSAWKSVQKVMSHPQALAQCHTFLQAELYGVEREVTPSTAYAAKWVSNNPTELV
LPVQAELVLPIQQQLMVAKENQAIWQQSQKILSHPQALAQSQMFLEKNFPEAILEATPSTAYAAKYIAEHPELPF
ATVVAEFVLPISQNLLALSKE....GKIEHIYSHPQALAQTRNYLREHYPQAKVEITDSTSAAAEFVKNHPDLPI
IQAVAEIVQPIHQQLMVVPGH....TKIEKIFSHPQALAQGKKFIDEQYPEAQIEVTASTAYAARFISEHPDQPF
LHIIGEYFMPIRFQLMVVPGVTK..DEIRTVHSHIHALGQCRKIIRSN..GWKPVIAGDTAGSARLVSEKGDRSM
LHIVGEYFMPIRFQLMVLPGVGR..EEIRTVHSHIHALGQCRKIVRAN..GWKPVVAGDTAGAAKLVKEVGDRSM
MHIVGEYFLPIHFQLMVLPGVRR..EEIKTVHSHIHALGQCRNVIRQN..GWKGVIAGDTAGAARLVADVKDRSM
MHIVGEYFLPIHFQLMVLPGVKR..DEIKTVHSHIHALGQCRKYIRKN..GWKAVVAGDTAGAAKMISEVKDRTM
LFIIGEWFLPVRHQLMAVKGAKI..SDIKSVESHVHALGQCRRIIRKL..GIKPIVHADTAGSARDISERKDKTV
LFIVGEWFLPIRHQLVAVPGAKL..EDIKTVESHVHALGQCRRIIRKF..GLKPIVAGDTAGSARIIAERGDKTC
LHIIAEHFERISHHLLAVPGATL..ATIKSVKSHVHALGQCRNLIREL..GLKVIVGTDTAGAAAELAERQDPTM
LHIIGEYYLPVRHCLMAHQGVNV..ERIHTVYSHPQALAQCHSFIKRH..GWNRVAVYDTAGAAAALKEEHREGE
VVILAETFVKVEHCLLGLPGASV..ETATKAMSHPQALVQCHNFFATHP.QIRAEAAYDTAGSAKMVAESRDKSA
LHVTGEVVVRVSHCLMALPGVEM..ADIRKVGSQQPALDQCTHLIREH..GWQPLAKHDTAGSAKDLAERGARDE
LSIVGEMTLTIDHCLLVSGTTDL..SAINTVYSHPQPFQQCSKFLNRYP.HWKIEYTESTSAAMEKVAQAKSPHV
LSIVGEMTVTIDHCVLVSGATDL..NTIETVYSHPQPFQQCSKFLSRYP.HWKIDYTESTSAAMEKVAQANSPRV
LSIVGELTLPIDHCVLVNGPTDL..QQIETVYSHPQPFQQCSQFINRFP.HWKIEYTESTAAAMEKVAALNSPKV
LSLVGELAYPIKHCVLVNDKTDL..NQIDTLYSHPQVIQQCSQFIHSLD.RVHIEYCESSSHAMQLVASLNKPNI
LYIVGELTQPIEHCLVATQEIRL..EDLKVLYSHPQPHQQCSEFLSRLK.GVKLESCASTADAMKKVQELNRADV
MVICGEVELRIHHHLLVGETTKT..DNITRIYSHAQSLAQCRKWLDSH..YPSVERVAVSSNADAAKRVKSEWNS
IVICGEVELRIHHHLLVGETTKT..DRITRIYSHAQSLAQCRKWLDAH..YPNVERVAVSSNADAAKRVKSEWNS
ILVRGEVIISISQCLICDDFIDF..KDVHCILSHPQALAQCREYILNN..FPTAEVKTTESTVKALLGVNAKKGI
VFAHGEIRLDINFALYGNGTDSI..SDIKKVYSIAPAISQTTNYIHQH..QFDYDYVDSTIQSLTKIEN....GV
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AAIANEAAAEKYGLTIVRRGIHTHKNNHTRFLVLHKKKKAILPNNGENRGE.KTTLMITLP.ADYAGALYQVLSA
GVIANDMAASTYELKIVKRDIQDYRDNHTRFVILSPDENISFEVNSKLSSRPKTTLMVMLPQDDQSGALHRVLSA
AAIANEQAATSYQLDMLEKDIHDYDENRTRFAVLAKGKLSLPPYQVEPYTK.KTTMMVTLS.SDFSGALHQVLSA
AAIAPRMAASEYGLEIVQENAQDLELNQTRFFVLSRKPVSILLPKEE...E.KTSISVILP.NNMPGALHKVLST
AAIAPRMAANEYGLEIVKENAQDLELNQTRFFVLSRKPVSILLPKEE...E.KTSISVILP.NNMPGALHKVLST
AAIAPKLSAEMYDLTIVEKNIQDLSVNQTRFWVLGSENLAISFPLSE...K.KITLAITMP.SNVPGSLHKVLSV
AAVANSYAAKMYDLEIVAKNIQDLAGNSTRFWLLGKEKKSFDLLKTG...E.KVSLALTLP.DNLPGALHKAISV
AAVAPRSSAEEYGLELIAEDIQEMEANFTRFWVLGAEKPSIPLQAQT...E.KMSLALTLP.DNLPGALYKALST
AALAPRLAADLYGLDILAENVEDSENNVTRFVVLSRDENWAKRQ....SSDEIVVTTFVFNVRNIPAALYKAMGG
AALAPRLAADLYGLDIIAENVEDTDSNVTRFVVLSREESRVART....SKDELIITTFVFNVRNIPAALYKAMGG
AALAPRLAADLYGLDILEENVEDSENNVTRFVVLSKNKQWAARP....ENDERIVTTFVFRVRNVPAALYKALGG
AALSPALAATLYGLDIIEENVEDTDSNVTRFVVLTKSKQWAERP....SPDVKMMTTFIFRVRNVPAALYKAMGG
AAIASRLAAKIYGLDILAEDIEDEAHNTTRFVVLAREPKWAAQG....SGP..LVTTFVFRVRNLPAALYKALGG
AAISSRLAAKIYGLDILAEDIEDEAHNTTRFVVLAREPRWAVQG....SGK..LVTTFVFRVRNLPAALYKALGG
AAIASELAAEAYGLVSLKAGIEDAEHNTTRFVVLAREA.LEPNP....NQP..CVTTFVFRVRNVAAALYKALGG
AAIASALAAELYGLDLLAEQIQDSANNTTRFLIIAKDG.IIPMP....NVG..CKISLLFEVRHIPAALYKCLGG
LAIASKRAGELYGLDILKENLADEEWNITRFFCIAHENNPDISHLKVRPDVARQKTSIVFALPNEQGSLFRALAT
AAIASRRAAELYGLNILQTGVEDEPFNFTRFMVLSR.HAP.......EPSDAPHKTSLIFAVRHTPGFLLETLG.
AALGSEAGGTLYGLQVLERIEANQRQNFTRFVVLARKAIN.......VSDQVPAKTTLLMATGQQAGALVEALLV
AALGSEAGGMLHGLQVLERIAANQTQNITRFLVLARKAIN.......VSDQVPAKTTLLIATGQQAGALVEALLV
AALGSEAGGELYQLQVLERNLANQQQNHTRFIVLARKAIE.......VSDQVPAKTTLIMATGQQAGALVDALLV
AALGNEDGGKLYGLSVLKTNIANQENNITRFIVVAKEPRE.......VSSQIPTKTLLLMTTSQQAGALVDALLV
AAIGNSASGKLYGLQPIQGNIANQTENHTRFIVVARKPVD.......VSPQIPAKTTLIMSTSQEAGSLVSTLLV
AAIAGDMAASLYDLSKLHEKIEDRPDNSTRFLIIGNQEVP.........PTGDDKTSIIVSMRNKPGALHELLVP
AAIAGDMAAQLYGLSKLAEKIEDRPVNSTRFLIIGSQEVP.........PTGDDKTSIIVSMRNKPGALHELLMP
VAIGPERAAWLYNLKILEKDVQDIKENYTRFLVIAKRDSD.........YTGEDKTSIVFSVPNVPGSLYRALGV
AAIAPLGSGEAYGFTPIDTHIEDYPHNVTRFLVIKNQQQFD........QNATSLMFLITPMHDKPGLLASVLNT
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FAWRKLNLSKIESRPMKTGLGNYFFLIDVDKAYDEV.LLPGVTMELEALGFSVTVLGSYSSYWL..........
FSWRNLNLSKIESRPTKTGLGHYFFIIDIEKAFDDV.LIPGAMQELEALGCKVRLLGAYQSYQL..........
FAWRKLNLTKIESRPMKTGLGNYFFIIDVDCEADDV.LIPGVMQELEALGCGVELLGSYPCFFHTSLKLTEASS
FAWRDIDLSKIESRPLKTSLGEYFFLIDVLSEGKET.LVTNALDEIRLLGGKANKLGTYHVHRLQTT.......
FAWRDIDLSKIESRPLKTSLGEYFFLIDVLSEGKEV.LVTNALDEITLLGGTANKLGTYHVHRLQTN.......
FSWRGINLSKIESRPLKTKLGEYFFLMDLVKDQPEK.LIEAALTELELIGAEIKILGDYPIYVLSTL.......
FAWRDIDMTKIESRPLRTRLGQYFFNIDLVNNEKNNLKIPYALEELSGLGVKVRLLGNYAVYSLGEG.......
FAWRGIDLTKIESRPLKTALGEYFFIIDVDYTDKD..LVHFAQKELEAIGIQYKILGAYPIYPISDHGKERR..
FATNGINMTKLESYQLGGKFVATQFYADIEGHPDDE.PVRHALDELRFFSEKVRILGVYNGHAMRGKLNQS...
FATNGINMTKLESYQLGGKFVATQFYADIEGHPDDI.GVRHAMDELRFFSENVRILGTYPAHPMRGVL......
FATNGVNMTKLESYQLGGRFIATQFYADIEGHPEER.SVQLALEELRFFTKEVRILGVYKGSDIRGTQLLAAE.
FATNGINMTKLESYQLG.AFTATLFYADIEGHPDDP.LVKLALDELRFFSREVRILGVYPASESR.EQWKVAD.
FATNGVNMTKLESYMVDGNFFATQFYADVDGHPEDK.GLAFAIEELKFFSREFRIVGVYPGHPFRATFSETQQD
FATNGVNMTKLESYMVDGNFFATQFYADVEGHPEDR.NLAFALDELKFFSREFRIVGVYPGHPFRATFSER...
FATNGINMTRLESYMVGGEFAATQFYADVEGHPTQR.NLRLALEELDFFSHEVRILGVYPRHPFRMKQQGGGQ.
FATNGINLTRLESRPVAGRDWSYHFYLDFQGRMDQV.NVQQALEELKFYTHNMKVLGCYP.ESLRPESQGAL..
FALRGIDLTKIESRPSRKKAFEYLFYADFIGHREDQ.NVHNALENLREFATMVKVLGSYGVVNP..........
.ELRGLNLSRIESRPRRDRAWSYLMYVDIEGKASDP.QVAQALAGILVKASYAKIIGSYPAAQGTVQ.......
LRNHSLIMTRLESRPIHGNPWEEMFYLDIQANLESA.EMQKALKELGEITRSMKVLGCYPSENVVPVDPT....
LRNHNLIMTKLESRPIHGNPWEEMFYLDIQANLESQ.VMQSALKELGEITRSMKVLGCYPSENVVPVEPA....
LRQHNLIMSKLESRPINGNPWEEMFYIDVQGNLQSE.RMQQALQELQTMTRSLKVLGCYPSENVVPAEPGR...
FKKHQINMTKLESRPIYGKPWEEMFYLEIEANIHHP.DTKQALEELKNYSNYLKILGCYPSEIVKPVSV.....
LQRYGINMTKLESRPIMGNPWEEMFYVDLEAHIDSD.EMQQALAELTQLTRHLKVLGCYPSENVKPTQVKFI..
FHNNGIDLTRIETRPSRSGKWTYVFFIDFVGHHKEP.LIKDVLEKIGQEAVALKVLGSYPKAVL..........
FHSNGIDLTRIETRPSRSGKWTYVFFIDCMGHHQDP.LIKNVLEKIGHEAVALKVLGSYPKAVL..........
FAEKNINMTKIESRPSRKKFGEYVFWVDIEGHRKEE.RIKEALEDLKIKADFLKVIGSYPKFKMGK........
FALFNINLSWIESRPLKTQLGMYRFFVQADSAITTD..IKKVIAILETLDFKVEMIGAFN..............
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RVGYLGPEATFTNMAVSRFFP....EAEHVPYRTIPDCMDAAANGNVDYAVVPLENAIEGSVNITVDYLVH.EQP
KVGYLGPAATFTHLAVSSCFQN...GAEHVAYRTIPECIDAAVAGEVDFAFVPLENALEGSVNLTIDYLIH.EQP
KIGYLGPRGTFTEMAVQTLFDD...KNVLKPYRTIPDCMDSVANGDMDAAVVPVENAIEGSVNVTLDYLIH.KQR
KIAYLGPAASFTHAAAAKAFP....KEEMVAKSTIPDCIMAIEKEDVDVAVVPIENTIEGSVNITLDYLFH.FSS
KIAYLGPAASFTHSAAAKAFP....KEEMIAKSTIPDCIMAIEKEDVDVAVVPIENTIEGSVNITLDYLFH.FSS
KVGYLGPIGSFTYSATLAAFP....EATLMPYASIPACLKAIEQQEVAWSIIPIENTIEGTVNASIDYLYH.QAQ
KIAYLGPRGSFCSVVAETAFV....SEELFAYDSILDVIEAYDEGKCDFALVPIENSTEGTVNMSIDKIFH.DSK
KIAYLGPKGSFSHHVVQTAFP....HEELQAFANITDVIKAYEQGLVNYSVVPVENSIEGSVHETLDYLFH.QAH
RIAFQGEFGANSDMACR.DM...FPDMEPLPCPTFEDAFNAIENGEADLGMIPIENTLAGRVADIHHLLP..ESR
RISFQGDYGANSDMACR.DM...FPSMEPLPCQTFEDAFLAVENGEADLAMIPIENTIAGRVADIHHLLP..ESR
RISFQGEAGANSDTACR.NM...FPDMEPLPCPTFEDAFNAVETGAADLAMIPIENTLAGRVADIHYLLP..LAD
RISFQGEPGANSDTACR.NV...YPSMEPLPCPTFEDAFNAVETGKADLAMIPIENTIAGRVADIHHLLP..ESR
KIAFQGEPGANSHIAIV.EA...YPDAEPMPCATFEDALSAISSGEADLGMIPIENSVAGRVADIHHLLP..ASG
KIAFQGEPGANSHIAIS.DA...YPTAEAMPCATFEDALSAISSGEADLGMIPIENSVAGRVADIHHLLP..TSK
SIAFQGEPGAYSHLACR.NA...YPGMQPLPCATFEDTFAAVREGRARYAMIPIDNSVAGRVADVHHLMP..YAG
VVAFQGAHGAYSEQACR.EK...LPGYQSRPYKTFEDIFIAVEQGDAELGMLPVENSMAGVVSDSYDLLA..VHN
LIAYQGEPGAYSEIAAL.......RFGEPLPCESFDDVFSAVTEQKADYAVIPIENSLGGSIHQNYDLLL..RRP
AVAFQGNPGSYGEIAALNAL...PQVRETLGYPTFHEVARAVENGEADYGVLPVENSLMGAIHQSIDLLT..ETE
RIAFLGPKGSYSHLAARQYAARHFEQFIESGCAKFADIFNQVETGQADYAVVPIENTSSGAINDVYDLLQ..HTS
RIAFLGPKGSYSHLAARQYAARHFEQFIESGCAKFTDIFHQVETGQADYAVVPIENTSSGAINDVYDLLQ..HTS
RIAFLGPKGSYSHLAARNYASRHFDSMVECGCLKFHDIIKQVENGVADYAVMPIENTSSGSINDVYDLLQ..QTS
HIAFLGKRGSYSNLAARNYAARYQKQFVELGCQSFEQVFEKVQTGEADFGVLPLENTTSGAINEVYDLLQ..HTD
RVAFLGAKGSYSHLATREYFSRKNTELIELNCDHFKEVARTVESGHADYGVLPIENTSSGSINEVYDLLQ..HTT
KVAYLGPEGTFTQAAALKHFG...NAVISTPMAAIDEVFREVAAGAVNFGVVPVENSTEGAVNHTLDSFL..EHD
RVAYLGPEGTFSQAAALKHFG...HSVISKPMAAIDEVFREVVAGAVNFGVVPVENSTEGAVNHTLDSFL..EHD
KVGYLGPKGTFSEEAVFKYIEG.MKECEAIEFATIQDVVKSVAEGTCDEGILPVENSIEGSVNVSLDLLINDAEG
QLYYLGPKGTFSYLACRQYFS..ENEATFQPKSNLFEVIKAVADDDTSIGVVPIENSIEGTINIVADALA..QQD
   145Bant
   146Bsub
   144Bhal
   145Linn
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   145Efae
   141Llac
   141Spne
   140Atum
   140Rmel
   140Bsui
   140Mlot
   140Bjap
   140Rpal
   140Mmag
   140Magn
   138Ctep
   141Drad
   145Ecol
   145Styp
   145Eher
   145Hinf
   145Vcho
   141Paer
   141Pstu
   145Tten
   138Saur
LSIVGEITVPIQQHLLVHPQYADVWEEVYAVHSHPHAIAQCHKFLNEELKGVTARDMTSTSAAAQYVKEHPEEKI
LPIVGEMTLPIHQHLLVHPSRENAWKELDKIYSHSHAIAQCHKFLHRHFPSVPYEYANSTGAAAKFVSDHPELNI
LEIVADIVVPISQHFLVHPNQRD..NEIKKILSHPHAVAQCHEFLRSSYPGVEIEYMTSTAAAAQWVADHPNEPV
VPVVAEIVLPIAQHLMVHPAHKATWKSVQKVMSHPQALAQCHTFLQAELYGVEREVTPSTAYAAKWVSNNPTELV
VPVVAEIVLPIAQHLMVHPAHVSAWKSVQKVMSHPQALAQCHTFLQAELYGVEREVTPSTAYAAKWVSNNPTELV
LPVQAELVLPIQQQLMVAKENQAIWQQSQKILSHPQALAQSQMFLEKNFPEAILEATPSTAYAAKYIAEHPELPF
ATVVAEFVLPISQNLLALSKE....GKIEHIYSHPQALAQTRNYLREHYPQAKVEITDSTSAAAEFVKNHPDLPI
IQAVAEIVQPIHQQLMVVPGH....TKIEKIFSHPQALAQGKKFIDEQYPEAQIEVTASTAYAARFISEHPDQPF
LHIIGEYFMPIRFQLMVVPGVTK..DEIRTVHSHIHALGQCRKIIRSN..GWKPVIAGDTAGSARLVSEKGDRSM
LHIVGEYFMPIRFQLMVLPGVGR..EEIRTVHSHIHALGQCRKIVRAN..GWKPVVAGDTAGAAKLVKEVGDRSM
MHIVGEYFLPIHFQLMVLPGVRR..EEIKTVHSHIHALGQCRNVIRQN..GWKGVIAGDTAGAARLVADVKDRSM
MHIVGEYFLPIHFQLMVLPGVKR..DEIKTVHSHIHALGQCRKYIRKN..GWKAVVAGDTAGAAKMISEVKDRTM
LFIIGEWFLPVRHQLMAVKGAKI..SDIKSVESHVHALGQCRRIIRKL..GIKPIVHADTAGSARDISERKDKTV
LFIVGEWFLPIRHQLVAVPGAKL..EDIKTVESHVHALGQCRRIIRKF..GLKPIVAGDTAGSARIIAERGDKTC
LHIIAEHFERISHHLLAVPGATL..ATIKSVKSHVHALGQCRNLIREL..GLKVIVGTDTAGAAAELAERQDPTM
LHIIGEYYLPVRHCLMAHQGVNV..ERIHTVYSHPQALAQCHSFIKRH..GWNRVAVYDTAGAAAALKEEHREGE
VVILAETFVKVEHCLLGLPGASV..ETATKAMSHPQALVQCHNFFATHP.QIRAEAAYDTAGSAKMVAESRDKSA
LHVTGEVVVRVSHCLMALPGVEM..ADIRKVGSQQPALDQCTHLIREH..GWQPLAKHDTAGSAKDLAERGARDE
LSIVGEMTLTIDHCLLVSGTTDL..SAINTVYSHPQPFQQCSKFLNRYP.HWKIEYTESTSAAMEKVAQAKSPHV
LSIVGEMTVTIDHCVLVSGATDL..NTIETVYSHPQPFQQCSKFLSRYP.HWKIDYTESTSAAMEKVAQANSPRV
LSIVGELTLPIDHCVLVNGPTDL..QQIETVYSHPQPFQQCSQFINRFP.HWKIEYTESTAAAMEKVAALNSPKV
LSLVGELAYPIKHCVLVNDKTDL..NQIDTLYSHPQVIQQCSQFIHSLD.RVHIEYCESSSHAMQLVASLNKPNI
LYIVGELTQPIEHCLVATQEIRL..EDLKVLYSHPQPHQQCSEFLSRLK.GVKLESCASTADAMKKVQELNRADV
MVICGEVELRIHHHLLVGETTKT..DNITRIYSHAQSLAQCRKWLDSH..YPSVERVAVSSNADAAKRVKSEWNS
IVICGEVELRIHHHLLVGETTKT..DRITRIYSHAQSLAQCRKWLDAH..YPNVERVAVSSNADAAKRVKSEWNS
ILVRGEVIISISQCLICDDFIDF..KDVHCILSHPQALAQCREYILNN..FPTAEVKTTESTVKALLGVNAKKGI
VFAHGEIRLDINFALYGNGTDSI..SDIKKVYSIAPAISQTTNYIHQH..QFDYDYVDSTIQSLTKIEN....GV
   218Bant
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   217Bhal
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   211Spne
   211Atum
   211Rmel
   211Bsui
   211Mlot
   209Bjap
   209Rpal
   208Mmag
   208Magn
   213Ctep
   207Drad
   213Ecol
   213Styp
   213Eher
   213Hinf
   213Vcho
   207Paer
   207Pstu
   211Tten
   205Saur
AAIANEAAAEKYGLTIVRRGIHTHKNNHTRFLVLHKKKKAILPNNGENRGE.KTTLMITLP.ADYAGALYQVLSA
GVIANDMAASTYELKIVKRDIQDYRDNHTRFVILSPDENISFEVNSKLSSRPKTTLMVMLPQDDQSGALHRVLSA
AAIANEQAATSYQLDMLEKDIHDYDENRTRFAVLAKGKLSLPPYQVEPYTK.KTTMMVTLS.SDFSGALHQVLSA
AAIAPRMAASEYGLEIVQENAQDLELNQTRFFVLSRKPVSILLPKEE...E.KTSISVILP.NNMPGALHKVLST
AAIAPRMAANEYGLEIVKENAQDLELNQTRFFVLSRKPVSILLPKEE...E.KTSISVILP.NNMPGALHKVLST
AAIAPKLSAEMYDLTIVEKNIQDLSVNQTRFWVLGSENLAISFPLSE...K.KITLAITMP.SNVPGSLHKVLSV
AAVANSYAAKMYDLEIVAKNIQDLAGNSTRFWLLGKEKKSFDLLKTG...E.KVSLALTLP.DNLPGALHKAISV
AAVAPRSSAEEYGLELIAEDIQEMEANFTRFWVLGAEKPSIPLQAQT...E.KMSLALTLP.DNLPGALYKALST
AALAPRLAADLYGLDILAENVEDSENNVTRFVVLSRDENWAKRQ....SSDEIVVTTFVFNVRNIPAALYKAMGG
AALAPRLAADLYGLDIIAENVEDTDSNVTRFVVLSREESRVART....SKDELIITTFVFNVRNIPAALYKAMGG
AALAPRLAADLYGLDILEENVEDSENNVTRFVVLSKNKQWAARP....ENDERIVTTFVFRVRNVPAALYKALGG
AALSPALAATLYGLDIIEENVEDTDSNVTRFVVLTKSKQWAERP....SPDVKMMTTFIFRVRNVPAALYKAMGG
AAIASRLAAKIYGLDILAEDIEDEAHNTTRFVVLAREPKWAAQG....SGP..LVTTFVFRVRNLPAALYKALGG
AAISSRLAAKIYGLDILAEDIEDEAHNTTRFVVLAREPRWAVQG....SGK..LVTTFVFRVRNLPAALYKALGG
AAIASELAAEAYGLVSLKAGIEDAEHNTTRFVVLAREA.LEPNP....NQP..CVTTFVFRVRNVAAALYKALGG
AAIASALAAELYGLDLLAEQIQDSANNTTRFLIIAKDG.IIPMP....NVG..CKISLLFEVRHIPAALYKCLGG
LAIASKRAGELYGLDILKENLADEEWNITRFFCIAHENNPDISHLKVRPDVARQKTSIVFALPNEQGSLFRALAT
AAIASRRAAELYGLNILQTGVEDEPFNFTRFMVLSR.HAP.......EPSDAPHKTSLIFAVRHTPGFLLETLG.
AALGSEAGGTLYGLQVLERIEANQRQNFTRFVVLARKAIN.......VSDQVPAKTTLLMATGQQAGALVEALLV
AALGSEAGGMLHGLQVLERIAANQTQNITRFLVLARKAIN.......VSDQVPAKTTLLIATGQQAGALVEALLV
AALGSEAGGELYQLQVLERNLANQQQNHTRFIVLARKAIE.......VSDQVPAKTTLIMATGQQAGALVDALLV
AALGNEDGGKLYGLSVLKTNIANQENNITRFIVVAKEPRE.......VSSQIPTKTLLLMTTSQQAGALVDALLV
AAIGNSASGKLYGLQPIQGNIANQTENHTRFIVVARKPVD.......VSPQIPAKTTLIMSTSQEAGSLVSTLLV
AAIAGDMAASLYDLSKLHEKIEDRPDNSTRFLIIGNQEVP.........PTGDDKTSIIVSMRNKPGALHELLVP
AAIAGDMAAQLYGLSKLAEKIEDRPVNSTRFLIIGSQEVP.........PTGDDKTSIIVSMRNKPGALHELLMP
VAIGPERAAWLYNLKILEKDVQDIKENYTRFLVIAKRDSD.........YTGEDKTSIVFSVPNVPGSLYRALGV
AAIAPLGSGEAYGFTPIDTHIEDYPHNVTRFLVIKNQQQFD........QNATSLMFLITPMHDKPGLLASVLNT
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FAWRKLNLSKIESRPMKTGLGNYFFLIDVDKAYDEV.LLPGVTMELEALGFSVTVLGSYSSYWL..........
FSWRNLNLSKIESRPTKTGLGHYFFIIDIEKAFDDV.LIPGAMQELEALGCKVRLLGAYQSYQL..........
FAWRKLNLTKIESRPMKTGLGNYFFIIDVDCEADDV.LIPGVMQELEALGCGVELLGSYPCFFHTSLKLTEASS
FAWRDIDLSKIESRPLKTSLGEYFFLIDVLSEGKET.LVTNALDEIRLLGGKANKLGTYHVHRLQTT.......
FAWRDIDLSKIESRPLKTSLGEYFFLIDVLSEGKEV.LVTNALDEITLLGGTANKLGTYHVHRLQTN.......
FSWRGINLSKIESRPLKTKLGEYFFLMDLVKDQPEK.LIEAALTELELIGAEIKILGDYPIYVLSTL.......
FAWRDIDMTKIESRPLRTRLGQYFFNIDLVNNEKNNLKIPYALEELSGLGVKVRLLGNYAVYSLGEG.......
FAWRGIDLTKIESRPLKTALGEYFFIIDVDYTDKD..LVHFAQKELEAIGIQYKILGAYPIYPISDHGKERR..
FATNGINMTKLESYQLGGKFVATQFYADIEGHPDDE.PVRHALDELRFFSEKVRILGVYNGHAMRGKLNQS...
FATNGINMTKLESYQLGGKFVATQFYADIEGHPDDI.GVRHAMDELRFFSENVRILGTYPAHPMRGVL......
FATNGVNMTKLESYQLGGRFIATQFYADIEGHPEER.SVQLALEELRFFTKEVRILGVYKGSDIRGTQLLAAE.
FATNGINMTKLESYQLG.AFTATLFYADIEGHPDDP.LVKLALDELRFFSREVRILGVYPASESR.EQWKVAD.
FATNGVNMTKLESYMVDGNFFATQFYADVDGHPEDK.GLAFAIEELKFFSREFRIVGVYPGHPFRATFSETQQD
FATNGVNMTKLESYMVDGNFFATQFYADVEGHPEDR.NLAFALDELKFFSREFRIVGVYPGHPFRATFSER...
FATNGINMTRLESYMVGGEFAATQFYADVEGHPTQR.NLRLALEELDFFSHEVRILGVYPRHPFRMKQQGGGQ.
FATNGINLTRLESRPVAGRDWSYHFYLDFQGRMDQV.NVQQALEELKFYTHNMKVLGCYP.ESLRPESQGAL..
FALRGIDLTKIESRPSRKKAFEYLFYADFIGHREDQ.NVHNALENLREFATMVKVLGSYGVVNP..........
.ELRGLNLSRIESRPRRDRAWSYLMYVDIEGKASDP.QVAQALAGILVKASYAKIIGSYPAAQGTVQ.......
LRNHSLIMTRLESRPIHGNPWEEMFYLDIQANLESA.EMQKALKELGEITRSMKVLGCYPSENVVPVDPT....
LRNHNLIMTKLESRPIHGNPWEEMFYLDIQANLESQ.VMQSALKELGEITRSMKVLGCYPSENVVPVEPA....
LRQHNLIMSKLESRPINGNPWEEMFYIDVQGNLQSE.RMQQALQELQTMTRSLKVLGCYPSENVVPAEPGR...
FKKHQINMTKLESRPIYGKPWEEMFYLEIEANIHHP.DTKQALEELKNYSNYLKILGCYPSEIVKPVSV.....
LQRYGINMTKLESRPIMGNPWEEMFYVDLEAHIDSD.EMQQALAELTQLTRHLKVLGCYPSENVKPTQVKFI..
FHNNGIDLTRIETRPSRSGKWTYVFFIDFVGHHKEP.LIKDVLEKIGQEAVALKVLGSYPKAVL..........
FHSNGIDLTRIETRPSRSGKWTYVFFIDCMGHHQDP.LIKNVLEKIGHEAVALKVLGSYPKAVL..........
FAEKNINMTKIESRPSRKKFGEYVFWVDIEGHRKEE.RIKEALEDLKIKADFLKVIGSYPKFKMGK........
FALFNINLSWIESRPLKTQLGMYRFFVQADSAITTD..IKKVIAILETLDFKVEMIGAFN..............
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Next, the six Arabidopsis ADT protein sequences were aligned. These 
sequences were aligned separately from the bacterial PDT sequences because 
the diverse PDT sequences disrupted the ADT alignment and made analysis 
difficult. The goal of the ADT alignment was to identify amino acid sites that may 
be responsible for the distinction between an ADT that can accept both 
arogenate and prephenate (ADT1 and ADT2) and a solely arogenate-accepting 
ADT (ADT3 – ADT6). To investigate this, an amino acid site was highlighted if it 
fulfilled three criteria:  
1. There was a conserved amino acid between ADT1 and ADT2. 
2. There was a conserved amino acid between ADT3-ADT6. 
3. These two amino acids were different. 
The 18 amino acid sites that met these requirements are highlighted in 
yellow in Figure 15.  
 Then, the results from the PDT alignment and the ADT alignment were 
compared. First, the 40 amino acids conserved in the bacterial PDTs were 
located in the ADT alignment. The goal of this comparison was to identify amino 
acids that were common between the bacterial PDTs and ADT1 and ADT2 but 
different from ADT3 – ADT6. However, all 40 of these amino acids that were 
conserved among the bacterial PDTs are present in both the ADT1/ADT2 and 
ADT3 – ADT6 groups. In most cases, these amino acids were present in all six of 
the Arabidopsis ADTs. These sites are highlighted in blue in Figure 15. Since 
they are found in both of the ADT groups, it is unlikely that these amino acids can 
distinguish between a prephenate-accepting and a solely arogenate-accepting 
ADT. 
In an alternative approach, the 18 amino acid sites that were identified in 
the ADT alignment were located in the PDT alignment. Again, the goal of this 
comparison was to identify amino acid sites that were common between the 
bacterial PDT sequences and ADT1 and ADT2, but different from the amino acid 
in ADT3 – ADT6 at the same site. Due to the high level of diversity in the 
bacterial PDT sequences, only 16 of the 18 amino acid sites could be identified  
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Figure 15. Protein sequence alignment of Arabidopsis ADTs. 
Partial alignment of the 6 ADT protein sequences from Arabidopsis thaliana 
generated with DNAMAN. The transit peptide sequences have been removed. 
Blue highlight: 40 amino acid locations that were identified in the bacterial PDTs 
as similar in more than 75% of the PDT sequences; yellow highlight: the 18 
amino acid sites identified in the ADTs that differed between ADT1/ADT2 and 
ADT3 – ADT6; star: the 10 amino acid sites identified in the ADT alignment that 
contained both the amino acid from ADT1/ADT2 and the amino acid from ADT3 – 
ADT6 in the PDT sequences; question mark: the two amino acid sites identified 
in the ADTs that differed between ADT1/ADT2 and ADT3 – ADT6 that could not 
be found in the PDT sequences; arrow: the 6 amino acid sites identified in the 
ADT alignment that did not contain the amino acid found in ADT3 – ADT6 in the 
PDT sequences; green arrow: the amino acid position that corresponds to the 
Phe341Leu substitution in ADT5 (discussed in section 3.5). 
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    78AtPDL1.seq
    78AtPDL3.seq
    78AtPDL5.seq
    78AtPDL6.seq
    78AtPDL2.seq
    78AtPDL4.seq
RVAYQGVPGAYSEAAAGKAYPNCQAIPCDQFEVAFQAVELWIADRAVLPVENSLGGSIHRNYDLLLRHRLHIVGEVQL
RVAYQGVPGAYSEAAAGKAYPNCQAIPCDQFEVAFQAVELWIADRAVLPVENSLGGSIHRNYDLLLRHRLHIVGEVQL
RVAYQGVPGAYSEAAAGKAYPNCDAIPCDQFDVAFQAVELWIADRAVLPVENSLGGSIHRNYDLLLRHRLHIVGEVQI
RVAYQGVPGAYSEAAAGKAYPNSEAIPCDQFDVAFQAVELWIADRAVLPVENSLGGSIHRNYDLLLRHRLHIVGEVQI
RISFQGIPGAYSETAALKAFPNCETVPCEQFEAAFQAVELWLVDKAVLPIENSVGGSIHRNYDLLLRHRLHIVQEVHL
RVAYQGVRGAYSESAAEKAYPNCEAVPCEEFDTAFEAVERWLVDRAVLPIENSLGGSIHRNYDLLLRHNLHIVGEVKL
   156AtPDL1.seq
   156AtPDL3.seq
   156AtPDL5.seq
   156AtPDL6.seq
   154AtPDL2.seq
   154AtPDL4.seq
PVHHCLLALPGVRKEFLTRVISHPQGLAQCEHTLTKLGLNVAREAVDDTAGAAEFIASNNLRDTAAIASARAAEIYGL
PVHHCLIALPGVRKEFLTRVISHPQGLAQCEHTLTKLGLNVAREAVDDTAGAAEFIAANNIRDTAAIASARAAEIYGL
PVHHCLLALPGVRTDCVSRVISHPQALAQTEHSLDVLTPHAAREAFHDTAAAAEYISANDLHDTAAVASARAAELYNL
PVHHCLLALPGVRTDCITRVISHPQALAQTEGSLNKLTPKAAIEAFHDTAAAAEYIAANNLHDTAAVASARAAELYGL
PVNHCLLGVPGVKKEDIKCVLSHPQALDQCVNSLNNLG..IQRISAKDTATAAQTVSSSGKIDVGAIASVRAANIYGL
AVRHCLLANHGVNIEDLRRVLSHPQALAQCENTLTKLG..LVREAVDDTAGAAKQIAFENLNDAAAVASEKAAKIYGL
   232AtPDL1.seq
   232AtPDL3.seq
   234AtPDL5.seq
   234AtPDL6.seq
   230AtPDL2.seq
   230AtPDL4.seq
EILEDGIQDDVSNVTRFVMLAREPIIPRTDRPFKTSIVFAH..EKGTSVLFKVLSAFAFRDISLTKIESRPNHNRPIR
EILEDGIQDDASNVTRFVMLAREPIIPRTDRPFKTSIVFAH..EKGTCVLFKVLSAFAFRNISLTKIESRPNHNVPIR
QILADGIQDDPGNVTRFLMLAREPIIPRTDRPFKTSIVFAAQEHKGTSVLFKVLSAFAFRDISLTKIESRPHHNRPLR
QILADGIQDDAGNVTRFLMLARDPIIPRTDRPFKTSIVFAAQEHKGTSVLFKVLSAFAFRNISLTKIESRPHQNCPVR
DILAENIQDDVNNVTRFLILAREPMIPRTDRPYKTSIVFSL..EEGPGVLFKALAVFALRSINLSKIESRPQRRRPLR
NIVAKDIQDDCDNVTRFLMLAREPIIPGTNRLFKTSIVFSL..EEGPGVLFKALAVFALRQINLTKIESRPLRKHPLR
   297AtPDL1.seq
   302AtPDL3.seq
   299AtPDL5.seq
   299AtPDL6.seq
   286AtPDL2.seq
   282AtPDL4.seq
VVDDANVGTAKHFEYMFYVDFEASMAEARAQNALAEVQEFTSFLRVLGSYPMDMTPWSPTSSTSS.....
LVDEANVGTAKHFEYMFYIDFEASMAESRAQNALSEVQEFTSFLRVLGSYPMDMTSWSPSSSSSSSSTFS
VVGDGSFGTSKNFEYMFYVDFEASMAEPRAQNALAEVQEYTSFLRVLGSYPMDMTPWSMTSTEEA.....
VVGDENVGTSKHFEYTFYVDFEASMAEARAQNALAEVQEYTSFLRVLGSYPMDMTPWSTLPSEDV.....
VVDGSNNGSAKYFDYLFYIDFEASMADTRAQHALGHLQEFASFIRILGCYPMDLVR..............
ASGG.....LKYFDYLFYVDFEASMADEVAQNALRHLEEFATFLRVLGSYPVDTTML.............
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with certainty. The two sites that could not be identified are labeled with a 
question mark in Figure 15 and the 16 amino acid sites that could be identified 
are highlighted in yellow in Figure 14. Of these 16 sites, 10 had the amino acid in 
ADT1/ADT2 as well as the amino acid found in ADT3 – ADT6 (stars in Figure 
14). Therefore, these 10 amino acids were unlikely to be important for 
differentiating between a prephenate-accepting ADT and a solely arogenate-
accepting ADT. The remaining 6 sites, however, did not contain the amino acid 
found in ADT3 – ADT6, which indicated that these amino acids might be 
important for ADT vs. PDT distinction (arrows in Figure 14).  
 As a third approach, an alignment of CDT protein sequences was 
analyzed. This was done because these enzymes can accept both arogenate 
and prephenate as substrates, and the comparison of their sequences with the 
ADTs and PDTs might reveal which amino acids are important for prephenate 
recognition. The CDT sequences were obtained from Burkholderia pseudomallei 
(YP_109985.1), Acidovorax citrulli (ABM33045.1), Ilyobacter polytropus 
(YP_003967695.1), Bradyrhizombium diazoefficiens (NP_771201.1), and 
Pseudomonas aeruginosa (CDH69854.1). However, the CDTs were found to be 
too distinct from both the plant ADT and bacterial PDT protein sequences to 
provide any valuable information (data not shown).  
Therefore, the number of amino acid sites that might be important for 
distinguishing between a prephenate-accepting ADT and a solely arogenate-
accepting ADT could not be narrowed down any further. Six is a large number of 
sites to target for testing protein function, particularly if a combination of several 
of these sites is required for prephenate recognition. Therefore, it was concluded 
that it was not practical to determine the amino acid(s) that are responsible for 
this distinction through specifically targeting these 6 amino acids.  
 
3.2 Random mutagenesis   
The results of the in silico analysis indicated that it was not practical to use 
targeted codon mutagenesis to determine which amino acids are required for 
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distinguishing between a prephenate-accepting ADT and a solely arogenate-
accepting ADT. Therefore, it was decided to use another approach.  
First, a random mutagenesis method was tried. One advantage of random 
mutagenesis is that it is an unbiased method that does not require any 
knowledge regarding putative sites of interest in the sequence to be mutated. A 
second advantage of this method is that it has the capacity to generate a large 
library of mutants that can be screened for changes in function caused by the 
mutation(s). The goal of this method was to randomly mutate an arogenate-
specific ADT through error-prone PCR to introduce PDT function to the enzyme. 
Therefore, full-length ADT4 and ADT6 cDNA sequences (both solely arogenate-
accepting; Cho et al. 2007) were selected for random mutagenesis. The ADT4 
and ADT6 cDNA libraries were generated and transformed into pha2, the PDT-
knockout yeast strain, to test for mutants that had acquired PDT function. 
However, it was difficult to generate a sufficient number of transformants. Only 
2000 transformants were successfully generated. A subset of each library was 
sequenced, and approximately 15% of the sequences were identified as wild 
type. That means that of the 2000 transformants only approximately 1700 (85%) 
would be useful for the PDT screen. Many more transformants would need to be 
generated in order to exhaustively screen the libraries (Appendix A) and 
therefore it was concluded that the random mutation method would not be 
pursued any further.  
3.3 Domain swapping 
In a second approach it was decided to identify the domain (TP, catalytic, or 
ACT) that can distinguish between a prephenate-accepting ADT and a solely 
arogenate-accepting ADT. For this, a domain from a prephenate-accepting ADT 
was swapped with a domain from a solely arogenate-accepting ADT and the 
resulting “chimera” was tested for PDT function in a pha2 yeast complementation 
assay. If the chimera is able to complement the PDT knockout pha2 yeast strain, 
this indicates that the domain from the prephenate-accepting ADT contains 
sequences for prephenate recognition. ADT2 and ADT4 were initially chosen for 
this research. ADT2 was chosen for domain swapping because it displayed the 
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highest level of prephenate recognition of the six ADTs in biochemical analyses 
(240 M-1s-1; Cho et al. 2007). ADT4 was chosen because it had been previously 
studied by other members of the lab (White 2011; Karademir 2012), and has 
been identified as solely arogenate-accepting both in vitro and in vivo (Cho et al. 
2007; Bross et al. 2011).  
3.3.1 Generating ADT2/ADT4 chimeras 
Overlap extension PCR was used to assemble the ADTs with swapped 
domains (Figure 9).  In this method, two fragments are independently amplified 
from two different templates (Figure 9A). The 5’ fragment is amplified with a 5’ 
gene specific primer and a 3’ primer that incorporates 15-24 bp of the other 
template. Conversely, the 3’ fragment is amplified with a 3’ gene specific primer 
and a 5’ primer that incorporates 15-24 bp of the first template. Then, the two 
fragments are both used as templates in a third PCR reaction (Figure 9B) in 
which the overlapping sequences facilitate the annealing of the two fragments 
and can act as an extension starting point to generate the full-length chimera. 
Only the outer primers are used for this third PCR reaction.  
A schematic for the six full-length ADT2/ADT4 chimeras that were generated 
through overlap extension PCR is outlined in Figure 10. These chimeras were 
designed to contain every possible combination of the three domains from ADT2 
and ADT4. All initial PCR fragments generated are listed in Table 7 together with 
their expected length. PCR fragments were analyzed by gel electrophoresis to 
ensure that they were of appropriate length (Figure 16A).  
The fragments were then used in combination as templates for the overlap 
extension PCR to generate the full-length chimeras. Expected sizes are given in 
Table 7 and the corresponding electrophoresis results are shown in Figure 16B.  
After PCR amplification, the ADT chimera sequences were recombined into 
the donor vector. This recombination was facilitated by the att recombination 
sites that were integrated onto the 5’ and 3’ ends of the constructs by the outer 
Gateway® Recombination primers (Table 3; Figure 8). All inserts were 
sequenced and only inserts that contained the correct combination of domains 
and lacked PCR amplification errors were chosen. The chosen inserts were then
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Figure 16. ADT2/ADT4 chimeras. 
(A) Agarose gels of ADT2 and ADT4 fragments containing the 15-24 bp of 
overlapping sequences. These fragments were used as templates in the overlap 
extension PCR to produce Chimera 1 – Chimera 6. (B) Agarose gel of Chimera 1 
– Chimera 6.  
L: 1 Kb ladder. All gels are 1% agarose and all sizes are in Kb.   
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 recombined into the yeast compatible pAG423GAL-ccdB-ECFP destination 
vector.  
3.3.2 Complementation assay of ADT2/ADT4 chimeras 
To determine if Chimera 1 – Chimera 6 have PDT activity in vivo, they 
were transformed into the pha2 yeast strain for the complementation assay. Full-
length ADT2 was used as a positive control and full-length ADT4 was used as a 
negative control. In addition, yeast transformed with an empty destination vector, 
and untransformed yeast cells were used as negative controls.  
Yeast cells were grown for 24 hours in appropriately supplemented liquid 
SD media containing raffinose. Raffinose media was chosen as it neither inhibits 
nor induces expression from the GAL1 promoter in the destination vector 
(Weinhandl et al. 2014). The cells were spotted onto solid SD media plates 
supplemented as described previously (section 2.8). To ensure the reproducibility 
of the complementation results, two samples of yeast cells that were 
independently transformed with the same chimera were each spotted twice. 
Every complementation assay was repeated three times. The results for all 
replicates and repeats were identical. Therefore, a single set of representative 
data is shown.  
Differential growth in the yeast samples was observed by day 13.  
Therefore, only data from this day is shown in Figure 17. By this day, the yeast 
transformed with ADT constructs were able to grow on media supplemented with 
Phe, regardless of the carbon source used. The pha2 strain was unable to grow 
on any media as it is untransformed and contains no vector. Yeast transformed 
with an empty destination vector was able to grow on all media as long as it was 
supplemented with Phe. All yeast samples containing an ADT construct were 
unable to grow on glucose or raffinose media if it lacked Phe. As demonstrated 
previously (Bross 2011), ADT2 was able to grow on inducing selective media 
lacking Phe whereas ADT4 did not. These controls indicate that all yeast 
samples have the ability to grow on all carbon sources if fully supplemented, that 
the GAL1 promoter is only induced on media containing  
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Figure 17. Complementation of the pha2 phenotype for ADT2/ADT4 
chimeras. 
Growth of pha2 yeast samples for the ADT2/ADT4 complementation assay on 
day 13. On the left, diagrams for the full-length chimeric sequences are shown. 
ADT2 domains are shown in white and ADT4 domains are shown in purple. The 
samples were spotted at a cell density of 1 x 105 cells/mL on selective solid SD 
media containing glucose, raffinose or galactose. For each of these carbon 
sources, the samples were spotted on media containing Phe and media lacking 
Phe.  
pha2: un-transformed pha2 yeast; pDEST: yeast transformed with the empty 
destination vector; Glu: Glucose; Raf: raffinose; Gal: galactose; +Phe: media 
containing Phe; -Phe: media lacking Phe. 
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galactose, and only an ADT with PDT function is able to grow on inducing 
medium lacking Phe.  
Yeast expressing Chimera 1, Chimera 3 and Chimera 5 were unable to 
grow on galactose media lacking Phe. However, growth was observed for yeast 
transformed with Chimera 2, Chimera 4 and Chimera 6 (Figure 17). The ability of 
these chimeras to complement the PDT knockout pha2 phenotype indicates that 
they can act as PDTs. The only ADT domain common to these three chimeras 
was the ACT regulatory domain from ADT2. Therefore, it was concluded that the 
ACT regulatory domain contains the sequences that can confer PDT function to 
an arogenate-only ADT in vivo.  
 
3.4 Functional analysis of ADT2 and ADT5  
To confirm that the ACT domain is able to confer PDT activity to an 
arogenate-only ADT, seven constructs with swapped domains were generated 
using ADT2 and ADT5 as templates. Again, ADT2 was chosen for its ability to 
complement the PDT knockout yeast phenotype (Bross et al. 2011). ADT5 was 
chosen, like ADT4, because it is a solely arogenate-accepting ADT (Cho et al. 
2007; Bross et al. 2011). 
A schematic for the seven full-length ADT2/ADT5 chimeras that were 
generated through overlap extension PCR is shown in Figure 11. Chimera 7 – 
Chimera 10 are analogs to Chimera 1 – Chimera 4, respectively, to test if the 
ADT2 ACT domain confers PDT activity to the ADT5 sequence. Three additional 
chimeras (Chimera 11 – Chimera 13) were created to narrow down whether it 
was the N-terminal half, the C-terminal half, or the catalytic:ACT domain border 
of the ACT domain that contains the sequences that can confer PDT to an 
arogenate-only ADT. The construct borders for Chimera 11 – Chimera 13 are 
shown in the ADT protein sequence alignment in Figure 18.  
Primers were designed as described previously (Table 3; section 3.3.1), 
fragments and chimeras (Table 8) were amplified by PCR and overlap extension  
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Figure 18. Construct design for the N-terminal ACT domain. 
Protein sequence alignment of partial catalytic and ACT domains of the six 
Arabidopsis ADTs generated with DNAMAN. Dark blue: C-terminal catalytic 
domain sequences; light green: N-terminal ACT domain sequences; dark green: 
C-terminal ACT domain sequences; black lines: the borders of Chimera 11 – 
Chimera 13. Amino acid sites that were identified as different for ADT1 and ADT2 
vs. ADT3 – ADT6 are indicated in red. The SLEEG group was swapped between 
ADT2 and ADT5. All amino acid locations listed correspond to the location in the 
ADT5 protein sequence, with the exception of 4-V396L which corresponds to this 
location in the ADT4 sequence.  
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    78AtPDL1.seq
    78AtPDL3.seq
    78AtPDL5.seq
    78AtPDL6.seq
    78AtPDL2.seq
    78AtPDL4.seq
RVAYQGVPGAYSEAAAGKAYPNCQAIPCDQFEVAFQAVELWIADRAVLPVENSLGGSIHRNYDLLLRHRLHIVGEVQL
RVAYQGVPGAYSEAAAGKAYPNCQAIPCDQFEVAFQAVELWIADRAVLPVENSLGGSIHRNYDLLLRHRLHIVGEVQL
RVAYQGVPGAYSEAAAGKAYPNCDAIPCDQFDVAFQAVELWIADRAVLPVENSLGGSIHRNYDLLLRHRLHIVGEVQI
RVAYQGVPGAYSEAAAGKAYPNSEAIPCDQFDVAFQAVELWIADRAVLPVENSLGGSIHRNYDLLLRHRLHIVGEVQI
RISFQGIPGAYSETAALKAFPNCETVPCEQFEAAFQAVELWLVDKAVLPIENSVGGSIHRNYDLLLRHRLHIVQEVHL
RVAYQGVRGAYSESAAEKAYPNCEAVPCEEFDTAFEAVERWLVDRAVLPIENSLGGSIHRNYDLLLRHNLHIVGEVKL
   156AtPDL1.seq
   156AtPDL3.seq
   156AtPDL5.seq
   156AtPDL6.seq
   154AtPDL2.seq
   154AtPDL4.seq
PVHHCLLALPGVRKEFLTRVISHPQGLAQCEHTLTKLGLNVAREAVDDTAGAAEFIASNNLRDTAAIASARAAEIYGL
PVHHCLIALPGVRKEFLTRVISHPQGLAQCEHTLTKLGLNVAREAVDDTAGAAEFIAANNIRDTAAIASARAAEIYGL
PVHHCLLALPGVRTDCVSRVISHPQALAQTEHSLDVLTPHAAREAFHDTAAAAEYISANDLHDTAAVASARAAELYNL
PVHHCLLALPGVRTDCITRVISHPQALAQTEGSLNKLTPKAAIEAFHDTAAAAEYIAANNLHDTAAVASARAAELYGL
PVNHCLLGVPGVKKEDIKCVLSHPQALDQCVNSLNNLG..IQRISAKDTATAAQTVSSSGKIDVGAIASVRAANIYGL
AVRHCLLANHGVNIEDLRRVLSHPQALAQCENTLTKLG..LVREAVDDTAGAAKQIAFENLNDAAAVASEKAAKIYGL
   232AtPDL1.seq
   232AtPDL3.seq
   234AtPDL5.seq
   234AtPDL6.seq
   230AtPDL2.seq
   230AtPDL4.seq
EILEDGIQDDVSNVTRFVMLAREPIIPRTDRPFKTSIVFAH..EKGTSVLFKVLSAFAFRDISLTKIESRPNHNRPIR
EILEDGIQDDASNVTRFVMLAREPIIPRTDRPFKTSIVFAH..EKGTCVLFKVLSAFAFRNISLTKIESRPNHNVPIR
QILADGIQDDPGNVTRFLMLAREPIIPRTDRPFKTSIVFAAQEHKGTSVLFKVLSAFAFRDISLTKIESRPHHNRPLR
QILADGIQDDAGNVTRFLMLARDPIIPRTDRPFKTSIVFAAQEHKGTSVLFKVLSAFAFRNISLTKIESRPHQNCPVR
DILAENIQDDVNNVTRFLILAREPMIPRTDRPYKTSIVFSL..EEGPGVLFKALAVFALRSINLSKIESRPQRRRPLR
NIVAKDIQDDCDNVTRFLMLAREPIIPGTNRLFKTSIVFSL..EEGPGVLFKALAVFALRQINLTKIESRPLRKHPLR
   297AtPDL1.seq
   302AtPDL3.seq
   299AtPDL5.seq
   299AtPDL6.seq
   286AtPDL2.seq
   282AtPDL4.seq
VVDDANVGTAKHFEYMFYVDFEASMAEARAQNALAEVQEFTSFLRVLGSYPMDMTPWSPTSSTSS.....
LVDEANVGTAKHFEYMFYIDFEASMAESRAQNALSEVQEFTSFLRVLGSYPMDMTSWSPSSSSSSSSTFS
VVGDGSFGTSKNFEYMFYVDFEASMAEPRAQNALAEVQEYTSFLRVLGSYPMDMTPWSMTSTEEA.....
VVGDENVGTSKHFEYTFYVDFEASMAEARAQNALAEVQEYTSFLRVLGSYPMDMTPWSTLPSEDV.....
VVDGSNNGSAKYFDYLFYIDFEASMADTRAQHALGHLQEFASFIRILGCYPMDLVR..............
ASGG.....LKYFDYLFYVDFEASMADEVAQNALRHLEEFATFLRVLGSYPVDTTML.............
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PCR and the resulting PCR fragments were checked for the proper sizes by gel 
electrophoresis (Figure 19A and 19B).  
Chimera 7 – Chimera 13 were transformed into pha2 and were tested for 
PDT activity using the complementation assay previously described (section 
3.3.3). The same positive and negative controls were used with the exception 
that full-length ADT5 replaced ADT4 as a negative control (Figure 20). 
Differential growth was observed by day 11 and therefore images of yeast growth 
on this day are presented in Figure 20. Chimera 7, Chimera 9 and Chimera 11 
were unable to support yeast growth on inducing medium lacking Phe. However, 
Chimera 8 and Chimera 10, Chimera 12, and Chimera 13 were able to support 
yeast growth on this media. The only region that was common between these 
chimeras was the N-terminal half of the ACT domain from ADT2.  
Therefore, it was concluded that this region contains the sequences for 
the PDT activity of ADT2 and can confer PDT function to ADT5 in vivo. This area 
is defined by 38 amino acids that span from Phe286 to Leu323 in ADT2 (Figure 
18).  
  
3.5 in silico analysis of the N-terminal ACT domain 
 To identify the exact amino acids in the N-terminal ACT domain that can 
confer PDT function to an arogenate-only ADT, the protein sequence alignments 
were revisited. The purpose of this in silico analysis was to identify amino acid 
sites that were common between the bacterial PDT sequences and ADT1 and 
ADT2, but different from the amino acid in ADT3 – ADT6. Two sites fulfilled these 
criteria, the positions of which are indicated in Figure 18. At the first site, which 
corresponds to Phe341 in ADT5, ADT1 and ADT2 have a leucine (Leu) and 
ADT3 – ADT6 have a Phe. This position was substituted from a Phe to a Leu in 
the ADT5 sequence (5-F341L; Figure 12). At the second site, which corresponds 
to Ser345 in ADT5, ADT1 and ADT2 contain an asparagine (Asn) and ADT3 – 
ADT6 contain a serine (Ser). This position was substituted from a Ser to an Asn 
in ADT5 (5-S345N; Figure 12). A double 
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Figure 19. ADT2/ADT5 chimeras. 
(A) Agarose gels of ADT2 and ADT5 fragments containing the 15-24 bp of 
overlapping sequences. These fragments were used as templates in the overlap 
extension PCR to produce Chimera 7 – Chimera 13. (B) Agarose gel of Chimera 
7 – Chimera 13.  
L: 1 Kb ladder. All gels are 1% agarose and all sizes are in Kb.  
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Figure 20. Complementation of the pha2 phenotype for ADT2/ADT5 
chimeras. 
Growth of pha2 yeast samples for the ADT2/ADT5 complementation assay on 
day 11. On the left, diagrams for the full-length chimeric sequences are shown. 
ADT2 domains are shown in white and ADT5 domains are shown in green. The 
samples were spotted at a cell density of 1 x 105 cells/mL on selective solid SD 
media containing glucose, raffinose or galactose. For each of these carbon 
sources, the samples were spotted on media containing Phe and media lacking 
Phe.  
pha2: un-transformed pha2 yeast; pDEST: yeast transformed with the empty 
destination vector; Glu: Glucose; Raf: raffinose; Gal: galactose; +Phe: media 
containing Phe; -Phe: media lacking Phe
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 mutant was also generated that substituted both of these amino acids in ADT5 
(5-DM; Figure 12).  
 In addition, a group of amino acids upstream of these two sites differs 
between ADT1/ADT2 and ADT3 – ADT6 (Figure 18). The amino acids 
corresponding to this group in the bacterial PDTs more closely resembled the 
group in ADT1/ADT2 than ADT3 – ADT6. This group will be referred to as the 
SLEEG group, due to the N-SLEEG-C motif observed in this group in ADT1 and 
ADT2. This region was swapped between ADT2 and ADT5 and two constructs 
were designed: 5-SLEEG and 2-SLEEG. 5-SLEEG contained ADT5 sequences 
from the N-terminus of the transit peptide to the last amino acid of the SLEEG 
region (S331) and ADT2 sequences from the corresponding ADT2 site (G299) to 
the C-terminus of the ACT domain. 2-SLEEG contained the reciprocal of this.  
 For comparison, an amino acid site that differed between ADT1/ADT2 and 
ADT3 – ADT6, but was located in the C-terminal ACT domain, was chosen as a 
negative control. This site corresponds to L263 in ADT2, V396 in ADT4, and 
V397 in ADT5 (section 3.1; Figure 18) and was substituted for the ADT2 amino 
acid in ADT4 and ADT5.  
 
3.6 Functional analysis of sequences within the N-terminal ACT domain   
A schematic for the seven full-length ADT chimeras that were generated 
through overlap extension PCR is outlined in Figure 12.  
Primer design, fragment amplification and overlap extension PCR were 
performed as previously described (section 3.3.1) to generate the new 
constructs. For the generation of the point mutations, the primers contained 
nucleotide changes causing amino acid substitutions (Table 4). Primers for the 
amplification of 5-F341L contain a T>C substitution at nucleotide 1021, primers 
for 5-S345N contain G>A1034, primers for 5-DM contain both of these mutations, 
primers for 5-V397L contain G>T1189 and primers for 4-V396L contain 
G>C1186.  
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Fragments were amplified as previously described (section 3.3.1) and 
analyzed with gel electrophoresis to check for the proper sizes (Figure 21A; 
Table 9). The fragments were used as templates to generate the full-length 
chimeras through overlap extension PCR as previously described (section 3.3.1) 
with the exception of 5-SLEEG and 5-F341L. These chimeras could not be 
successfully amplified using the standard thermocycler program and thus were 
generated using the modified program described in Table 6. In this modified 
program, the primers were added to the reaction after 10 cycles at an annealing 
temperature of 55°C. This was done to ensure that amplification would only occur 
once the fragments had annealed. Then, the polymerase would extend from the 
overlapping sequences, generating the full-length chimeras. The full-length 
products are then used as a template in the remaining cycles after the outer 
primers are added. All chimeras were analyzed by gel electrophoresis to ensure 
that they were of appropriate length (Figure 21B; Table 9).  
The chimeras were tested then for PDT function in a complementation 
assay as previously described (section 3.3.3), with the exception that both full-
length ADT4 and ADT5 were used as negative controls.  
Differential growth of the chimeras was observed by day 13 and therefore 
images of yeast growth on this date are presented in Figure 22. 5-SLEEG was 
unable to grow on fully supplemented SD media. Therefore, it was concluded 
that this chimera was unsuccessfully transformed into the pha2 yeast strain and it 
was not considered for further study. 2-SLEEG, 5-S345N, 5-V397L, and 4-V396L 
were unable to support growth on inducing medium lacking Phe. However, 5-
F341L and 5-DM were both able to complement the PDT knockout phenotype on 
this medium. The only substitution that these two chimeras have in common is 
the Phe341Leu substitution, in which a Phe was substituted for a Leu at amino 
acid position 341 in ADT5.  Therefore, it was concluded that the substitution of a 
Leu for Phe at amino acid position 341 in ADT5 can result in the introduction of 
PDT function to this arogenate-only ADT.  
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Figure 21. N-terminal ACT domain chimeras. 
(A) Agarose gels of ACT domain fragments containing the 15-24 bp of 
overlapping sequences. These fragments were used as templates in the overlap 
extension PCR to produce 5-F341L, 5-S345N, 5-DM, 5-SLEEG, 2-SLEEG, 4-
V396L and 5-V397L. (B) Agarose gel of 5-F341L, 5-S345N, 5-DM, 5-SLEEG, 2-
SLEEG, 4-V396L and 5-V397L chimeras. 
L: 1 Kb ladder. All gels are 1% agarose and all sizes are in Kb.  
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Figure 22. Complementation of the pha2 phenotype for N-terminal ACT 
domain chimeras. 
Growth of pha2 yeast samples for the N-terminal ACT domain complementation 
assay on day 13. On the left, diagrams for the full-length chimeric sequences are 
shown. ADT2 domains are shown in white, ADT4 domains are shown in purple, 
and ADT5 domains are shown in green. The samples were spotted at a cell 
density of 1 x 105 cells/mL on selective solid SD media containing glucose, 
raffinose or galactose. For each of these carbon sources, the samples were 
spotted on media containing Phe and media lacking Phe.  
pha2: un-transformed pha2 yeast; pDEST: yeast transformed with the empty 
destination vector; Glu: Glucose; Raf: raffinose; Gal: galactose; +Phe: media 
containing Phe; -Phe: media lacking Phe. 
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3.7 Protein induction and expression in pha2 Saccharomyces cerevisiae 
 Many of the ADT chimeras were unable to support growth of the pha2 
yeast strain. It was important to ensure that the chimeras were expressed under 
inducing conditions, otherwise the lack of yeast growth could be due to an 
inability of the yeast to express the chimeras instead of a lack of PDT activity.  
 Total soluble protein (TSP) was extracted from pha2 yeast cells that 
contained a single ADT protein and grown in liquid inducing media and a western 
blot was performed as previously described (section 2.7; Figure 23). Equal 
protein concentrations were size separated on an SDS PAGE gel, transferred 
onto a nitrocellulose membrane and used for the western blot.  
As all of the ADT proteins are ECFP fusion proteins, they were probed 
with an anti-GFP antibody. Anti-GFP was used because ECFP and GFP are 
similar enough that this antibody can detect both proteins. A GFP standard was 
also loaded as a positive control to ensure that the anti-GFP antibody could bind 
to GFP. Yeast transformed with full-length ADT2, ADT4 and ADT5 were 
analyzed as positive controls. Yeast transformed with Chimera 11 and grown in 
non-inducing conditions (“non-induced yeast”), yeast transformed with an empty 
destination vector, and untransformed yeast were analyzed as negative controls.  
ECFP was seen in all of the positive controls, but it was not detected in 
the negative controls. A band of approximately 27 kDA was detected in the yeast 
transformed with an empty destination vector (“pDEST” in Figure 23), which 
corresponds to the 27.7 kDa size of the ECFP fusion protein, confirming that 
ECFP can be detected with the GFP antibody.  
ECFP was detected for all of the ADT-ECFP fusion proteins with the 
exception of 5-SLEEG (Figure 23), which was considered to be untransformed. 
For all samples, the top band corresponds to the expected size of the chimera 
protein (Table 9) with the fusion protein attached. In addition, a band that is 
approximately 10 kDa smaller was seen in yeast samples that were transformed 
with Chimeras 2, 3, 7, 5-V397L, and full-length ADT5. Ten kDa corresponds to   
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Figure 23. Expression of ADT constructs in pha2 yeast. 
Western blots of all ADT constructs. Total soluble protein was isolated and 
quantified using a BCA assay, 15 µg of total soluble protein was size separated 
on 10% SDS-PAGE and Western blots were exposed for 1 min. (A) Western blot 
containing ADT2/ADT4, ADT2/ADT5, and C-terminal ACT domain amino acid 
substitution constructs and positive and negative controls. The concentration of 
the GFP standard (lane 1) in this blot is 150 ng/µL. Due to the high signal 
observed for this standard this concentration was decreased in (B).  (B) Western 
blot containing the N-terminal ADT2/ADT5 chimeras and ADT5 mutants, and full-
length ADT2 and ADT5. The GFP standard concentration in this blot in 75 ng/µL.  
GFP: GFP standard; pha2: empty pha2 yeast; pDEST: yeast transformed with 
the empty pAG423GAL-ccdB-ECFP; N: yeast transformed with Chimera 11 but 
grown under non-inducing conditions (glucose). All sizes are in kDa.  
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the approximate size of the transit peptide. This indicates that the transit peptide 
is cleaved in these samples, and the smaller band represents the cleavage 
product that lacks the transit peptide. ADT-ECFP fusion proteins without the 
transit peptide can still be detected by the GFP antibody because the ECFP tag 
is at the C-terminus of the protein. In addition, a small band corresponding to the 
size of the transit peptide was also detected in yeast transformed with Chimeras 
3, 5, 6, 7, 8, 12, 5-V397L and full-length ADT5. This indicates that the ECFP is 
cleaved in these samples.   
In conclusion, all of the ADT-ECFP fusion proteins (with the exception of 
5-SLEEG) can be detected and hence are translated by the pha2 yeast. 
Therefore, the lack of growth that was seen in many of these samples in the 
complementation assay is due to a lack of PDT activity and not an inability of the 
yeast to express the protein.  
 
3.8 3D Homology modeling of the ACT domain 
The results of the pha2 complementation assays indicate that a Phe to 
Leu substitution at amino acid position 341 in ADT5 was able to confer PDT 
activity to this enzyme. It is possible that the change in substrate specificity 
observed in this altered ADT is due to a conformational change that is caused by 
the Phe341Leu substitution. There is no structural information available for any of 
the plant ADTs, which makes it difficult to confirm this prediction. However, there 
are computer programs that can predict a protein’s structure by modeling its 
sequence against that of a related protein with a known structure, using it as a 
structural template. Based on the template’s structural information, this “3D 
homology modeling” can predict what the overall conformation of the 
uncharacterized protein will look like. For this study, a program named UCSF 
Chimera was used to homology model the structure of ADT2 and ADT5. The 
goal of this modeling was to predict whether the Phe341Leu substitution in ADT5 
has an impact on its surrounding amino acids or the ADT5 overall conformation, 
therefore altering the substrate specificity of this enzyme. The amino acid 
position in ADT2 that corresponds to this substitution is Leu317. It was expected 
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that the Phe341Leu substitution’s interactions with its surrounding residues 
would more closely resemble those of the Leu317 in ADT2 than the Phe341 in 
ADT5. In addition, it was expected that this substitution would alter the ADT5 
overall structure to make it more similar to ADT2, a prephenate-accepting ADT.  
First, the structure of ADT2 was predicted. To do this, a protein template 
with a known crystal structure had to be chosen. A BLAST search was performed 
to determine the most similar amino acid sequence for which there was a crystal 
structure available in the Protein Data Bank (PDB). The PDT protein from C. 
tepidum (Ct-PDT; QMXW) had the highest similarity to the ADT2 sequence. Ct-
PDT, as described in section 1.6, is a homodimer. However, only a single chain 
or subunit can be modeled at a time with the UCSF Chimera program (Figure 
24A). Therefore, the ADT2 sequence was modeled after the Ct-PDT monomer. 
The location of Leu317 was identified in the homology modeled ADT2 structure. 
The location of Leu317 in ADT2 was predicted to be in an α-helix in the ACT 
domain (Figure 24B). This correlates with the ACT dimer interface in Ct-PDT, 
and the site of Phe ligand binding. Then, the “FindHbond” tool was used to 
predict potential hydrogen bonds between Leu317 and it’s surrounding amino 
acids. This tool predicted that Leu317 forms a hydrogen bond with Ala313 
(Figure 24B).  
As with ADT2, a BLAST search was performed with the ADT5 sequence 
and it was found that Ct-PDT had the highest similarity to the ADT5 sequence. 
ADT5 was modeled against Ct-PDT and the position of Phe341 was identified 
(Figure 25A). Similar to Leu317, Phe341 was predicted to be in the α-helix that 
lies at the ACT domain interface and Phe ligand binding site in the Ct-PDT dimer. 
A potential hydrogen bond between Phe341 and Ser337 was predicted with the 
“FindHBond” tool (Figure 25B). Interestingly, Ser337 in ADT5 corresponds to the 
same amino acid position as Ala313 in ADT2. So, both Leu317 in ADT2 and 
Phe341 in ADT5 are predicted to form hydrogen bonds with the amino acids 4 
positions towards their N-terminus. Then, the “Rotamers” tool was used to 
substitute Phe341 to a Leu in the 3D homology modeled ADT5. This tool can 
substitute an amino acid and will also predict the possible rotations in space in 
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Figure 24. Leu317 and the 3D homology model for ADT2. 
(A) 3D homology model for an ADT2 monomer. This model is based on the 
structural information the monomer of the PDT protein from Chlorobium tepidum 
(Ct-PDT) using the UCSF Chimera program. (B) Zoomed in view of the ADT2 
ACT domain to highlight the position of Leu317 (green). The predicted hydrogen 
bond between Leu317 and Ala313 (blue) is shown in orange.  
	  102	  
	  
Leu317'
Ala313'
B'A'
	  103	  
	  
 
 
 
 
 
 
 
 
Figure 25. Phe341 in the 3D homology modeled ADT5. 
(A) ADT5 homology modeled monomer. The ADT5 sequence was homology 
modeled against the monomer of the PDT homodimer from Chlorobium tepidium 
(Ct-PDT) using UCSF Chimera’s “Modeller” program. (B) Zoomed view of 
Phe341 (green), the amino acid required for PDT activity in ADT2. The predicted 
hydrogen bond between Phe341 and Ser337 is shown in orange. (C) Zoomed 
view of Leu341 (green), which was substituted for Phe341. The predicted 
hydrogen bond between Leu341 and Ser337 is shown in orange.  
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which the new amino acid might exist. The tool assigns a probability to each of 
these different “rotamers”. Nine rotamers were identified for ADT5 and all of 
these rotamers were predicted to form a hydrogen bond with the same Ser337. 
The rotamer that was predicted with the greatest probability (75.3%) is shown in 
Figure 25C. The “Clashes and Contacts” tool was used to predict if any of the 
rotamers could physically interact with their surrounding amino acids, possibly 
resulting in a displacement those surrounding amino acids or an overall 
conformational change in the protein. However, no clashes or contacts were 
identified for any of the nine rotamers (data not shown).  
In summary, the predictions made by the UCSF Chimera program do not 
indicate that the Phe341Leu substitution in ADT5 has any substantial effects on 
interactions with amino acids in its nearby surroundings or the overall protein 
conformation.  
 
4 Discussion  
The main goal of this study was to identify the amino acids that can 
distinguish between ADTs and PDTs. To accomplish this, a family of six 
Arabidopsis ADTs, two of which have PDT function (ADT1 and ADT2) and four of 
which are only ADTs (ADT3 – ADT6) were studied. Three members of this 
family, ADT2, ADT4 and ADT5 were chosen for analysis through domain 
swapping and yeast complementation assays. Nineteen ADT chimeras were 
generated through overlap extension PCR to consist of Arabidopsis sequences 
from ADT2, which is a prephenate-accepting ADT, and ADT4 or ADT5, which are 
solely arogenate-accepting ADTs. The chimeras were tested for PDT activity in a 
pha2 PDT knockout yeast strain. I was able to identify that a Phe to Leu 
substitution at amino acid position 341 in ADT5 can confer PDT function to this 
arogenate-only ADT.  
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4.1 Complementation results  
S. cerevisiae is a useful organism in which to study protein function 
because it can be grown as a haploid and therefore the allele it carries 
determines its phenotype. If one allele is knocked out, the gene function is 
eliminated in the yeast strain entirely. A mutant S. cerevisiae yeast strain named 
pha2 was used for the complementation assay in this study. S. cerevisiae has a 
single PDT coding sequence (PHA2), making it an ideal candidate for this assay. 
When PHA2 is knocked out, the strain is unable to synthesize Phe and can only 
survive if either an exogenous supply of Phe is provided or a gene with PDT 
activity is transformed into and expressed in the yeast (Bross et al. 2011). Hence, 
this provides a simple way to identify PDT activity in a strain that contains an 
altered protein. Yeast growth indicates that the protein can complement the pha2 
phenotype and therefore has PDT activity. Lack of yeast growth indicates that the 
protein cannot complement the pha2 phenotype, and therefore does not have 
PDT activity. This pha2 complementation assay has already been successfully 
used to test the six Arabidopsis ADTs for PDT function (Bross et al. 2011). In this 
study, ADT1 and ADT2 were able to complement the pha2 phenotype and ADT3 
– ADT6 were not. Hence, ADT1 and ADT2 have PDT function and ADT3 – ADT6 
do not.  
ADT domain swapping chimeras were tested for PDT activity using the 
pha2 complementation assay. The region that can confer PDT function to an 
arogenate-only ADT was systematically narrowed down to a single amino acid 
position. This amino acid was a Phe to Leu substitution at amino acid position 
341 in ADT5, which conferred PDT activity to this enzyme. This position was 
previously identified in an in silico approach (section 3.1) as a position which 
could potentially distinguish between ADT and PDT function. It was first identified 
in the Arabidopsis ADTs (green arrow in Figure 15), because it fulfilled three 
requirements: that there was a conserved amino acid between ADT1 and ADT2 
(Leu), that there was a conserved amino acid between ADT3 – ADT6 (Phe), and 
that these two amino acids are different.  
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Then, this position was located in the bacterial PDT sequences (green arrow in 
Figure 14). Importantly, Leu was identified at this position in the PDTs, while Phe 
was not. However, although Leu is present at this position in some of the 
bacterial sequences, it is not highly conserved. In fact, it is only found in only 3 of 
the 26 sequences in the alignment in Figure 14. In addition, several other amino 
acids such as Trp, Thr, Asn Arg, and Lys are found at this position. Interestingly, 
these amino acids have a wide range of different characteristics: Leu and Trp are 
nonpolar and hydrophobic, Thr and Asn are polar and hydrophilic, and Arg and 
Lys are positively charged. This indicates that Leu is not the only amino acid at 
this position which can confer PDT function.  
 To check if the presence of a Leu at position 341 in ADT5 can be used to 
predict PDT function in plant ADTs, the Arabidopsis ADT sequences were 
compared to ADT sequences from P. hybrida. The P. hybrida ADT sequences 
are the only other plant ADTs which have been biochemically analyzed (Maeda 
et al. 2010). There are three enzymes in the P. hybrida ADT family, Ph-ADT1, 
Ph-ADT2 and Ph-ADT3 (ACY79502.1, ACY79503.1, ACY79504.1, respectively) 
all of which function predominantly as ADTs. However, Ph-ADT2 and Ph-ADT3 
can also convert prephenate to phenylpyruvate (act as PDTs). An alignment of 
the P. hybrida and the Arabidopsis ADT sequences is shown in Figure 26. 
Interestingly, neither of the prephenate-accepting Ph-ADTs have a Leu at the 
amino acid position corresponding to the Phe341Leu substitution that resulted in 
PDT function in ADT5. In fact, Ph-ADT2 has a Met while Ph-ADT3 has an Ala. 
This does not indicate that a Leu at this position can be used to predict PDT 
function in plant ADTs. However, Ph-ADT1, which is solely arogenate-accepting, 
has Phe at this location. This is the amino acid also found in the arogenate-
specific Arabidopsis ADT3 – ADT6 at this position. This could indicate that a Phe 
at this position might define ADT function, rather than a Leu at this position 
defines PDT function. If this is the case, it is possible that many amino acids at 
this position can allow for the acceptance of prephenate as a substrate but only a 
Phe at this location eliminates prephenate recognition. Consistent with this 
assumption, none of the bacterial PDT sequences that were  
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Figure 26. Analysis of Leu317 from Arabidopsis and Petunia ADT 
sequences. 
Alignment of partial catalytic and ACT domain sequences from the six 
Arabidopsis ADTs (At-ADT1 – At-ADT6) and the three Ph-ADT sequences from 
Petunia hybrida (Ph-ADT1 – Ph-ADT3) generated with DNAMAN. At-ADT1, At-
ADT2, Ph-ADT2, and Ph-ADT3 are all predominantly arogenate-accepting but 
also have a low level of prephenate recognition. All other enzymes in this 
alignment are solely arogenate-accepting. Sequences from the N-terminal 
catalytic domain are highlighted in blue and sequences from the C-terminal ACT 
domain are highlighted in green. The position of Phe341Leu, the amino acid 
substitution that conferred PDT function to ADT5, is highlighted in red. The amino 
acid number at this position differs between the ADT enzymes because the 
lengths of the transit peptides in these enzymes are highly variable. At this 
position: the ADTs with PDT function have a Met (Ph-ADT2), an Asn (Ph-ADT3), 
or a Leu (At-ADT1 and At-ADT2) whereas all of the solely arogenate-accepting 
ADTs contain a Phe (Ph-ADT1 and At-ADT3 – At-ADT6).   
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analyzed carried a Phe at the corresponding position in the bacterial alignment 
(green arrow in Figure 14).  
So, distinguishing between an ADT and a PDT based on this amino acid 
position alone might be more complicated than originally anticipated. A Phe at 
this position clearly allows for ADT function in ADT5, but future studies will need 
to be completed to determine if this is a more general phenomena.  
However, the results from the complementation analysis in this study 
clearly show that a Phe to Leu substitution at amino acid position 341 can confer 
PDT function to ADT5, an arogenate-specific ADT. Although this may be 
surprising, there are many examples in the literature in which a single amino acid 
change has altered the function of an entire protein. For example, a single amino 
acid change in a cathepsin L protease that is secreted by the trematode Fasciola 
hepatica altered this enzyme’s substrate specificity (Smooker et al. 2000). The 
altered protein is able to cleave substrates with a proline at the cleavage site, 
whereas the native protein cannot. In another example, a single amino acid 
substitution in an aspartate aminotransferase from E. coli changed the pH 
dependence of the enzyme (Jeffery et al. 2000). This change alters the kinetic 
parameters of the enzyme, allowing the enzyme to recognize its aspartate 
substrate at a different pH. In both of these examples, the amino acid substitution 
responsible for the change in enzymatic activity is located outside of the catalytic 
site. Importantly, both substitutions result in a change in the overall conformation 
of the protein. This suggests that the overall protein conformation is more 
important for function than the protein sequence.  One could argue that PDT 
enzymes themselves are an example of this hypothesis. For example, the PDT 
enzymes from C. tepidum and S. aureus display very similar overall conformation 
and function although their sequences are very distinct (only 27.3% identical 
(Tan et al. 2008). Therefore, a substitution that does not affect the catalytic site 
directly can substantially alter enzyme catalysis if it results in an overall 
conformational change that transfers the effects of the substitution to the catalytic 
site.  
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4.2 The importance of the ACT domain  
The Phe341Leu substitution that conferred PDT function to ADT5 is 
located in the N-terminal region of the ACT domain. This was surprising since it 
is more intuitive that the amino acid required for prephenate recognition would be 
located in the catalytic domain, rather than the ACT domain. Characteristically, 
ACT domains are ligand-binding domains that can be found in a diverse group of 
metabolic enzymes that are regulated by allosteric binding of amino acids to this 
domain (Grant 2006; Liberles et al. 2005). The effects of ligand binding to the 
ACT domain are transferred to the catalytic site and can either inhibit or activate 
enzymatic activity (Grant 2006). 
The enzymatic activity of the bacterial PDTs is allosterically inhibited by 
Phe binding to the ACT domain. The site of Phe binding in PDTs is in the N-
terminal region of the ACT domain, and the amino acids that form the 
hydrophobic Phe-binding pocket are highly conserved among these enzymes 
(Tan et al. 2008). The two most highly conserved amino acid motifs in this region 
are the GALV and ESRP motifs, which are essential to Phe binding and feedback 
inhibition (Pohnert et al. 1999). These amino acids contribute directly to 
interactions with the Phe ligand as well as the formation of the closed ACT 
domain conformation. These amino acids correspond to G209SLF and E229SRP 
in Ct-PDT (Figure 27A).  
The GALV and ESRP motifs are also very highly conserved within the plant 
ADTs (Tan et al. 2008). These amino acids correspond to G297PGVL and 
E319SRP in Arabidopsis ADT2 (Figure 27B) and G328TSVL and E350SRP in 
ADT5 (Figure 27C) and are essential for Phe binding. In fact, a substitution of 
S320A in Arabidopsis ADT2 substantially decreased Phe-induced feedback 
inhibition of enzymatic function and increased the free Phe levels 160-fold 
(Huang et al. 2010). An S298I substitution in the ESRP motif in an Oryza sativa 
ADT also decreased Phe-induced inhibition of this enzyme (Yamada et al. 2008). 
This indicates that these motifs are required for Phe binding in plant ADTs, and 
that changes in this area of the ACT domain can indirectly affect the catalytic site 
in these enzymes as well. Although the Phe341Leu substitution in ADT5 is not 
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part of the GALV or ESRP motif it is located right in between them (Figure 27B).  
Therefore, it is understandable that this amino acid change could also indirectly 
affect substrate recognition.  
Due to a lack of structural information, the mechanism of allosteric Phe 
inhibition in the plant ADTs is unknown. However, this mechanism has been 
determined in two bacterial PDTs (Tan et al. 2008). Crystal structures of the 
PDTs from C. tepidum and S. aureus indicate that Phe binding in the ACT 
domain results in an overall conformational change in these proteins, reducing 
the access of prephenate to the catalytic cleft in the catalytic domain.  
These PDT enzymes form homodimers in which the two catalytic domains 
and the two ACT domains are closely aligned (Figure 4; Tan et al. 2008). An 
extended catalytic cleft, which hosts the active site, forms between the two 
catalytic domains. Interestingly, the N-termini of several α-helices from both 
monomers point into this cleft, making it highly positive (about 3.0 positive 
charges; (Hol 1985). This attracts prephenate, which is negatively charged, to the 
active site. When Phe is not bound to the ACT domain the dimer exists in an 
open conformation in which prephenate can access the catalytic cleft. However, 
when two Phe molecules simultaneously bind to two hydrophobic pockets at the 
ACT dimer interface, the ACT domains shift closer together. This movement is 
transferred throughout the entire protein, resulting in an overall change in 
conformation that splits the catalytic cleft and reduces the access of prephenate 
to the active site. Figure 5 shows a schematic of this conformational change. 
During this change, several of the positively charged α-helix N-termini that point 
into the cleft are rotated, decreasing the attractive positive charge near the active 
site. Therefore, it has been conclusively shown that amino acids in the region of 
the Ct-PDT and Sa-PDT ACT domain that correspond to the region of the 
Phe341Leu substitution in ADT5 can cause an overall change in protein 
conformation and indirectly affect the ability of prephenate to bind at the active 
site.  
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Figure 27. GALV and ESRP motifs in Ct-PDT, ADT2 and ADT5.  
The amino acid site corresponding to Leu317 in ADT2 is in close proximity to 
highly conserved GALV and ESRP motifs in the Ct-PDT protein and the ADT2 
and ADT5 homology models. (A) The GALV and ESRP motif in the Ct-PDT 
dimer, which correspond to G209SLF and E229SRP in each monomer, 
respectively. The motifs from monomer A (blue) are shown in light blue and the 
motifs from monomer B (red) are shown in pink. Leu220 from each monomer is 
indicated in green. (B) The GALV and ESRP motifs (P298GVL and E319SRP, 
respectively) and Leu317 in the ADT2 homology model. The motifs are shown in 
blue, and Leu317 is shown in green. (C) The GALV and ESRP motifs 
(G328TSVL and E350SRP, respectively) and Phe341, the amino acid that 
corresponds to Leu317 in ADT2, in the ADT5 homology model. The motifs are 
shown in pink, and Phe341 is shown in green.  
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Although there is no structural information available for the plant ADTs, the 
protein conformation of these enzymes can be predicted with a 3D homology 
modeling computer program such as UCSF Chimera. This program can model a 
protein sequence with unknown structure against a known protein structural 
template. Using the PDT from C. tepidum as a template, the overall conformation 
of Arabidopsis ADT2 and ADT5 was predicted in order to determine whether the 
Phe341Leu substitution in ADT5 has an impact on its surrounding amino acids or 
the ADT5 overall protein conformation (section 3.8). The predictions made by the 
UCSF Chimera program did not indicate that the Phe341Leu substitution in 
ADT5 has any substantial effects on interactions with its nearby amino acids or 
the overall protein conformation. However, since these interactions are predicted 
based on data from the PDT protein, they may not accurately reflect the actual 
ADT amino acid interactions or protein conformation in vivo. In addition, since the 
program can only model a single chain or subunit at one time, only interactions 
within an ADT monomer could be predicted.  
Dimerization is required for both catalytic function and Phe feedback 
inhibition in the bacterial PDTs (Tan et al. 2008). Interestingly, it has been shown 
that all six of the Arabidopsis ADTs can form homo and heterodimers in planta 
(Styranko 2011). However, whether or not this dimerization is required for ADT 
catalytic function or Phe inhibition in the ADTs is currently unknown. Therefore, 
we cannot yet predict whether the Phe341Leu substitution in the ACT domain of 
ADT5 results in an overall change in protein dimer conformation similar to the 
change described for the bacterial PDTs (Tan et al. 2008).  
 
4.3 Future directions 
Using a pha2 yeast complementation assay, it was identified that the 
Phe341Leu substitution in ADT5 introduced PDT function to this enzyme. To 
ensure that this substitution can confer PDT function to the other solely 
arogenate-accepting ADTs, future research should substitute this amino acid 
position in ADT3, ADT4 and ADT6 as well. As well, the Phe at this position in the 
other arogenate-only ADTs could be substituted to one of the other amino acids 
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found at this position in the bacterial PDTs (Trp, Thr, Asn Arg), to determine if 
this confers PDT function. In addition, since the in silico analysis indicated it may 
be the lack of the Phe at this position that confers PDT function as opposed to a 
presence of Leu specifically, Leu317 should be substituted for Phe in ADT2. If a 
Phe at this position is in fact responsible for removing PDT function, it is 
expected that the Leu317Phe substituted ADT2 would lose PDT function and 
therefore not be able to complement the pha2 phenotype.  
However, the pha2 complementation analysis can only determine if a 
protein has PDT activity, it cannot be used to test whether the altered ADT 
proteins have retained or lost their ADT activity. Therefore, it is important that all 
of the altered proteins are tested through biochemical analysis to determine 
whether these proteins can still recognize arogenate as a substrate.  
The lack of structural information available for the plant ADTs greatly 
hinders our ability to understand substrate recognition and Phe inhibition in these 
proteins. Future research should concentrate on determining crystal structures 
for both the unaltered ADT proteins as well as those containing the ACT domain 
substitution that alter substrate recognition. This structural information will reveal 
whether the catalytic and allosteric inhibition mechanisms described for the 
bacterial PDTs (Tan et al. 2008) are similar in the Arabidopsis ADTs. 
 
4.4 Conclusions 
This study represents the first characterization of an amino acid that can 
potentially distinguish between ADT and PDT function. Through the generation of 
domain swapping ADT chimeras and a series of pha2 yeast complementation 
assays, I have identified that Phe341Leu, a single amino acid substitution in the 
ACT domain of ADT5, results in PDT function to this arogenate-only ADT. This 
study is an example of the ability of a single amino acid outside of the catalytic 
site to substantially impact enzymatic activity. These results also emphasize the 
importance of the ACT domain and the need to understand its role in indirectly 
affecting substrate recognition and protein function. As Phe is a building block of 
protein synthesis and a precursor to a wide variety of important secondary 
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metabolites in plants, understanding the enzymes involved in its biosynthesis 
pathway is important to regulating and manipulating the synthesis of this 
essential amino acid.  
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6 Appendices  
Appendix A.  
The number of mutants that must be generated and screened in order to 
exhaustively search a randomly mutated library can be calculated with the 
following equation:  
 
# mutants = bk x n!/(n-k)! 
 
“b” represents the number of different bases the wild type nucleotide could be 
changed to. “b” will always equal 3, because one of the four nucleotides 
(A,T,G,C) must be substituted to a different nucleotide to result in a mutation. “k” 
represents the number of nucleotide mutations that must be introduced in order 
to alter gene function and “n” represents the length of the sequence to be 
mutated (in nucleotides).  
 
For example, in order to introduce 4 nucleotide mutations to a sequence that is 
10 nucleotides in length through random mutagenesis:  
 
# mutants = 34  x 10!/(10-4)! 
# mutants = 408240 
 
408240 mutants would need to be generated and screened. For a full-length ADT 
gene of approximately 1200 bp, this number is essentially infinite. Therefore, it 
was deemed that random mutagenesis is not a practical method for determining 
the sequences required for PDT function in the prephenate-accepting 
Arabidopsis ADTs.
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